The QualityStocks Daily Monday, June 3rd, 2024

Today's Top 3 Investment Newsletters

QualityStocks(AFMD) $7.3300 +68.51%

CannabisNewsWire(GTVH) $0.0022 +57.14%

360 Wall Street(BPTH) $3.2300 +56.80%

The QualityStocks Daily Stock List

Affimed NV (AFMD)

MarketClub Analysis, MarketBeat, StockMarketWatch, QualityStocks, Marketbeat.com, PoliticsAndMyPortfolio, TradersPro, BUYINS.NET, StreetInsider, Schaeffer's, Trading Concepts, Barchart, FreeRealTime, Investment U, InvestorPlace, OTCtipReporter, PennyStockScholar, Wall Street Mover, Profitable Trader Authority, Stock Beast, The Online Investor and PennyStockProphet reported earlier on Affimed NV (AFMD), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Affimed NV (NASDAQ: AFMD) is a clinical-stage biopharmaceutical firm that is engaged in the discovery and development of cancer immunotherapies.

The firm has its headquarters in Heidelberg, Germany and was incorporated in 2000. Prior to its name change in October 2014, the firm was known as Affimed Therapeutics B.V. It serves consumers around the globe, with a focus on Germany, Europe and the United States. The firm generates the majority of its revenue from the United States.

The company is party to collaboration agreements with Roche Holding AG, Roivant Sciences Ltd, Genentech Inc., and the University of Texas MD Anderson Cancer Center. It also has a research funding agreement with the Leukemia & Lymphoma Society. The company is focused on providing a unique approach to fighting cancer using its scientific team, which has extensive expertise in immunity and cell engager-based medicines. Its objective is to overcome the challenges and limitations faced by the current immune-oncology therapies.

The enterprise’s product portfolio comprises of its AFM13 formulation, which in different phases of clinical trials evaluating its effectiveness in treating transformed mycosis fungoides, peripheral T-cell lymphoma, hodgkin lymphoma and CD30-positive T-cell lymphoma. It also develops a cell-engaging bi-specific antibody formulation dubbed AFM26, for the treatment of multiple myeloma, as well as its AFM24 formulation, which has been developed to treat advanced cancers.

The company is focused on progressing its parallel development strategy for some of its formulations and advancing its broad development pipeline, which it expects will generate an ongoing stream of data over the coming quarters.

Affimed NV (AFMD), closed Monday's trading session at $7.33, up 68.5057%, on 30,869,903 volume. The average volume for the last 3 months is 2.358M and the stock's 52-week low/high is $2.235/$8.82.

Bio-Path Holdings (BPTH)

StockMarketWatch, MarketBeat, MarketClub Analysis, Wall Street Resources, QualityStocks, The Online Investor, Schaeffer's, INO Market Report, Marketbeat.com, PoliticsAndMyPortfolio, TraderPower, StreetInsider, 360 Wall Street, MicroCap Gems, The Stock Dork, Tim Bohen, TopStockAnalysts, InvestorsUnderground, Daily Markets and OTC Markets Group reported earlier on Bio-Path Holdings (BPTH), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Bio-Path Holdings Inc. (NASDAQ: BPTH) is a clinical stage oncology firm that is focused on the development of treatments for challenging cancers, which include chronic myeloid leukemia and acute myeloid leukemia.

The firm has its headquarters in Bellaire, Texas and was incorporated in 2007, on May 10th by Ana Tari Ashizawa, Gabriel Lopez-Berestein, Douglas P. Morris and Peter Nielsen. It operates as part of the scientific research and development services industry, under the healthcare sector. The firm serves consumers in the United States, with a focus on the state of Texas.

The company uses its novel technology to achieve systemic delivery for target specific protein inhibition for gene products that are over-expressed in disease. It develops products based off of a drug delivery and antisense technology which uses P-ethoxy, known as DNAbilize. P-ethoxy is a DNA backbone modification that’s been designed to protect the DNA from destruction.

The enterprise’s product pipeline is comprised of a formulation dubbed prexigebersen, which is undergoing phase 2 clinical trials evaluating its effectiveness in treating myelodysplastic syndrome and acute myeloid leukemia. It is also developing prexigebersen-A for solid tumors; Liposomal STAT3, which is in preclinical stage for the treatment of pancreatic cancer; and Liposomal Bcl-2, for the treatment of chronic lymphocytic leukemia and refractory/relapsed lymphoma.

The firm recently announced its third quarter financial results for 2021, with its CEO noting that they had made regulatory and clinical advances in two of its clinical trials. It is focused on achieving its goal to bring new medicines for cancer into the market.

Bio-Path Holdings (BPTH), closed Monday's trading session at $3.23, up 56.7961%, on 56,969,666 volume. The average volume for the last 3 months is 167,212 and the stock's 52-week low/high is $1.85/$44.80.

Rare Element Resources (REEMF)

MarketBeat, QualityStocks, TradersPro and InvestorIntel reported earlier on Rare Element Resources (REEMF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Rare Element Resources Ltd. (OTCQB: REEMF) is a strategic materials firm engaged in exploring for mineral properties, with a focus on rare earth products for technology, energy and defense applications.

The firm has its headquarters in Littleton, Colorado and was incorporated in 1999, on June 3rd by Mark Thomas Brown. It operates as part of the other industrial metals and mining industry, under the basic materials sector. The firm serves consumers around the globe, with a focus on those in the United States.

The company operates through the exploration of mineral properties segment. It is focused on delivering strategic materials to technology industries by advancing plans to develop the Bear Lodge Property, located in northeast Wyoming. This property is located 7 air miles (11km) or 12 road miles (19km) northwest of the town of Sundance, Wyoming. The property contains 2 projects; the Bear Lodge Critical Rare Earth (REE) Project, which is located near the town of Sundance in northeast Wyoming; and the Sundance Gold Project. The Bear Lodge REE Project comprises of the Bull Hill mineral district, inclusive of the Bull Hill and Whitetail Ridge deposits and the exploration targets of East Taylor and Carbon. The identified REE deposits and occurrences within the Bear Lodge Property alkaline complex are contained within the company’s block of unpatented lode mining claims.

The firm remains focused on advancing exploration efforts at its properties and advancing its rare earth demonstration plant plans, in a bid to scale-up production while still creating value for its shareholders.

Rare Element Resources (REEMF), closed Monday's trading session at $0.3151, up 18.816%, on 385,523 volume. The average volume for the last 3 months is 117.074M and the stock's 52-week low/high is $0.1312/$0.989.

Crown Electrokinetics (CRKN)

QualityStocks, StockEarnings, AwesomeStocks, Early Bird, Fierce Analyst, Investors Underground, MarketClub Analysis, Small Cap Firm, Zacks, StockStreetWire, 360 Wall Street, PennyStockProphet, Mega Stock Alerts, StockWireNews, The Online Investor, The Stock Dork, Tim Bohen, Timothy Sykes and Premium Stock Alerts reported earlier on Crown Electrokinetics (CRKN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Crown ElectroKinetics Corp (NASDAQ: CRKN) is focused on the commercialization of electrokinetic technology.

The firm has its headquarters in Corvallis, Oregon and was incorporated in 2015, on April 20th by Timothy Koch, James Douvikas and Douglas B. Croxall. Prior to its name change in October 2017, the firm was known as 3D Nanocolor Corp. The firm serves consumers in the United States.

The enterprise develops and sells optical switching film which can be applied to the surface of glass or other rigid substrates like acrylic, to control opacity electronically. The film can also be embedded between sheets of smart glass powered by solar strips. The enterprise’s electro kinetic film technology, which is derived from microfluidic and ink technology, uses nanometer-sized particles of pigments which have been charged electrically and suspended in a liquid sandwiched between substrates coated with a transparent conductor oxide film. The film enables transitions between dark and clear, which allows individuals to prevent and/or manage glare, control the tint of the skylight, block out ultraviolet rays, decrease carbon emissions, and decrease the amount of heat entering the home. The enterprise’s offerings can be applied to a range of windows, including automotive sunroofs, residential windows and skylights and commercial buildings.

The company recently entered into an agreement with Hudson Pacific Properties, which involves the installation of energy-saving smart window inserts at some of the properties Hudson owns on the West Coast. This move will not only help Hudson Pacific reduce carbon emissions and energy consumption from cooling and heating systems by at least 25%, but also bring in additional revenue to Crown Electrokinetics and help extend the company’s consumer reach.

Crown Electrokinetics (CRKN), closed Monday's trading session at $0.1179, up 17.9%, on 298,463,243 volume. The average volume for the last 3 months is 347,888 and the stock's 52-week low/high is $0.0414/$11.70.

CV Sciences, Inc. (CVSI)

QualityStocks, InvestorPlace, OTCtipReporter, PennyStockScholar, Profitable Trader Authority, MarketBeat, MarketClub Analysis, Wall Street Mover, Buzz Stocks, Promotion Stock Secrets, Planet Penny Stocks, Wealth Insider Alert, The Street Report, Daily Trade Alert, PennyStockProphet, Stock Commander, TopPennyStockMovers, The Street, StockOnion, StreetAuthority Daily, PoliticsAndMyPortfolio, Market Intelligence Center Alert, Damn Good Penny Picks, StreetInsider, Penny Picks, StockEarnings and Money Morning reported earlier on CV Sciences, Inc. (CVSI), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

CV Sciences, Inc. operates as a life science company. It operates two distinct business segments - a Consumer Products Division and a Drug Development Division. The Company’s PlusCBD Oil is the top-selling brand of hemp-derived CBD on the market, according to SPINS, the foremost provider of syndicated data and insights for the natural, organic and specialty products industry. CV Sciences has main offices and facilities in San Diego, California and Las Vegas, Nevada.

CV Sciences’ Consumer Product division focuses on manufacturing, marketing and selling hemp-based CBD products to a range of market sectors. The Consumer Products Division delivers botanical‐based cannabidiol products. At present, these are distributed nationally in health food stores, health care provider’s offices, and also online.

The Drug Development division focuses on developing and commercializing novel therapeutics utilizing CBD (cannabidiol). This Division is developing synthetically‐formulated cannabidiol‐based medicine, pursuing the approval of the U.S. Food and Drug Administration (FDA) for drugs with specific indications using cannabidiol as the active pharmaceutical ingredient. CV Sciences states that it has attained promising preclinical results in the development of cannabinoid medicines for the treatment of an array of medical conditions.

CV Sciences, Inc. (CVSI), closed Monday's trading session at $0.08, up 17.6471%, on 2,160,033 volume. The average volume for the last 3 months is 8.343M and the stock's 52-week low/high is $0.0275/$0.095.

PAO Group (PAOG)

StockRockandRoll, PennyStockLocks, Penny Stock 101, MoneyTV, Penny Investor Network, MarketClub Analysis and InvestorPlace reported earlier on PAO Group (PAOG), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

PAO Group Inc. (OTC: PAOG) is a holding firm that is focused on developing alternate medicine clinics which focus on non-traditional patient care solutions.

The firm has its headquarters in Sandusky, Ohio and was incorporated in 2003, on June 23rd. It operates as part of the medical care facilities industry, under the healthcare sector. The firm mainly serves consumers in the United States.

The company recently revitalized its mission to advance medical cannabis technologies with a pair of complimentary acquisitions. One is of a cannabis cultivation operation and one of a cannabis biopharmaceutical asset. The cannabis biopharmaceutical asset, RespRx, is derived from a patented botanical extraction process - U.S. Patent No. 9,199,960. The patented intellectual property includes the existing and ongoing research and development for the company, focusing on the development of pharmaceuticals to treat various illnesses, diseases and chronic pain. The company also owns an emerging cannabis cultivator concentrating on hemp cultivation within the United States and marijuana cultivation in Canada.

The enterprise is advancing the future of biopharmaceutical technology derived from cannabis. Its treatment solutions include cannabis, acupuncture, chiropractic, biofeedback, and other solutions depending upon patient needs. It also offers pain management, massage therapy, nutritional counseling, and hormone replacement.

At the moment, the firm remains focused on entering into collaborations and partnerships that will boost its revenues and extend its consumer reach. This move will also open the firm up to new growth and investment opportunities while creating new avenues to generate value for its shareholders.

PAO Group (PAOG), closed Monday's trading session at $0.0004, off by 20%, on 17,919,070 volume. The average volume for the last 3 months is - and the stock's 52-week low/high is $0.000001/$0.0033.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO)

Green Car Stocks, InvestorPlace, QualityStocks, StocksEarning, Kiplinger Today, Schaeffer's, MarketClub Analysis, StockMarketWatch, TradersPro, GreenCarStocks, StockEarnings, BUYINS.NET, Trades Of The Day, MarketBeat, The Street, TopPennyStockMovers, Zacks, Daily Trade Alert, The Online Investor, Small Cap Firm, SmallCapVoice, VectorVest, Eagle Financial Publications, Cabot Wealth and PoliticsAndMyPortfolio reported earlier on ElectraMeccanica Vehicles Corp. Ltd. (SOLO), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

The recent drop in electric vehicle demand that has left many automakers rethinking their electrification plans may be short-lived. New data shows that while the drop in EV sales may have forced major carmakers such as General Motors (GM) and Ford to scale down their plans amid mounting losses in their electric car divisions, the slowdown may not be as bad and won’t last as long as previously predicted.

To help cut emissions from the transportation segment, the Biden administration invested tens of billions of dollars into developing America’s nascent electric-vehicle sector and building a network of public charging infrastructure via the 2022 Inflation Reduction Act. However, EV sales in most major markets started to fall in late 2023 and continued falling through 2024 due to high electric vehicle prices, high interest rates and rising living costs.

With major companies such as Tesla, GM and Ford struggling to sell their EVs, many experts predicted the slowdown would last through the year and possibly into the next, especially if prices and interest rates remained at current levels. A Bloomberg report now says that sales data from Q1 2024 indicates that the ongoing sales slowdown is a minor bump in a journey that will see rising electric vehicle sales every year.

The report suggests that consumer purchases don’t seem to be affected by demand issues and Tesla is still the only mass EV producer in the U.S. despite its somewhat disappointing delivery numbers. Cox Automotive director of industry insights Stephanie Valdez-Streaty says the nascent EV sector is still experiencing demand growth but noted that the pace isn’t standard industry-wide.

She adds that although Ford and Tesla may not have any new models on the way, BMW, Cadillac, Kia and Hyundai are pushing forward. Even so, Tesla still holds a majority of the U.S. EV market, with the Model Y accounting for 34.5% of the country’s total market share and more than 30% of Q1 EV sales.

The Model 3, Rivian R1S and Ford F-150 Lightning made up 3.5%, 2.9% and 2.8% of total market share. Analysts say established automakers will have to reach mass levels of EV production to even dream of shaking Tesla’s dominance in the U.S. market. Bloomberg forecasts a surge in electric vehicle sales growth through the year, with Ford, General Motors and Hyundai selling more than 100,000 electric cars this year, a threshold that only Tesla has reached in the nation so far.

This is good news for ElectraMeccanica Vehicles Corp. Ltd. (NASDAQ: SOLO) and the overall industry as concerns were beginning to arise regarding the future viability of strategic plans that these companies had made for the future.

ElectraMeccanica Vehicles Corp. Ltd. (SOLO), closed Monday's trading session at $0.2122, even for the day. The average volume for the last 3 months is 25.068M and the stock's 52-week low/high is $0.1999/$1.04.

Lucid Motors (LCID)

Green Car Stocks, InvestorPlace, StockEarnings, Schaeffer's, QualityStocks, The Street, MarketBeat, Early Bird, MarketClub Analysis, StocksEarning, GreenCarStocks, Investopedia, INO Market Report, Daily Trade Alert, Kiplinger Today, The Online Investor, Money Wealth Matters, Trades Of The Day, BillionDollarClub, The Wealth Report, Louis Navellier, Zacks, The Night Owl, DividendStocks, FreeRealTime, Cabot Wealth, Wealth Whisperer, Top Pros’ Top Picks, The Stock Dork, InsiderTrades, InvestorsUnderground, AllPennyStocks, Smartmoneytrading and Green Energy Stocks reported earlier on Lucid Motors (LCID), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

Lucid Motors NASDAQ: LCID), an American manufacturer of luxury electric vehicles, plans to lay off 400 employees, which is about 6% of its headcount. Last year, the company laid off 1,300 employees. This is part of Lucid Motors’ strategic move to deal with slower growth and streamline operations for future success.

When the company announced plans to lay off employees, it sent ripples through the industry. This news came at a pivotal moment for the company, which plans to launch its first electric Gravity SUV before the end of the year.

Lucid Motors said that the restructuring will be completed by the third quarter. It plans to spend about $25 million on the restructuring process, allowing it to be better poised by the time the SUV is launched. This expansion is aimed at attracting a larger market share and solidifying its dominance in the electric vehicle (EV) industry amid increasing competition and consumer demand for diverse EV options.

According to CEO Peter Rawlinson, layoffs will impact all levels of employees, from leadership to mid-level management, except those working hourly in manufacturing and logistics. The immediate impact of these layoffs is profound and has raised many concerns about job security in the EV market. However, the company said all those affected by the layoff will receive severance packages and job-placement assistance.

So why is Lucid Motors making such a move? The news on the streets is that the company is struggling with slow growth, losses and consumer sentiment being at an all-time low about the EV industry. Additionally, the company is also dealing with various challenges, including supply-chain disruptions and rising production costs, which are affecting the company’s profitability. To make things worse, the state of the world is not doing well. The economic uncertainties felt worldwide and the increasing cost of raw materials has put extra pressure on the production of EVs.

In response to these extreme challenges, Lucid Motors is planning strategic realignment to lower production costs and improve its operational efficiency. According to Rawlinson, the move is aimed at helping the company be more vigilant about resources. This way, management can optimize resources so that the company will be better positioned for success and growth opportunities in the future while also focusing on achieving the company’s goals.

However, according to industry experts, the layoffs will likely have a ripple effect on the remaining employees’ morale. In the immediate future, the EV manufacturer may experience disruptions as it tries to adapt to a reduction in the workforce. However, in the long run, these layoffs could help stabilize the company’s financial health and boost its competitiveness in the EV market.

Lucid Motors (LCID), closed Monday's trading session at $2.83, off by 0.3521127%, on 21,495,502 volume. The average volume for the last 3 months is 909,744 and the stock's 52-week low/high is $2.29/$8.37.

Curaleaf Holdings Inc. (CURLF)

InvestorPlace, QualityStocks, Kiplinger Today, MarketBeat, Cabot Wealth, Daily Trade Alert, Top Pros' Top Picks, The Online Investor, MarketClub Analysis, Profit Trends, Wealth Insider Alert, StreetInsider, Early Bird, Trading For Keeps, Trades Of The Day, The Street, Prism MarketView, TradersPro, Zacks, Schaeffer's, Investment U, StreetAuthority Daily, wyatt research newsletter, Daily Profit, CFN Media Group, CannabisNewsWire and Wyatt Investment Research reported earlier on Curaleaf Holdings Inc. (CURLF), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A bipartisan initiative aiming at terminating federal enforcement of marijuana laws in states where it is legal has the backing of two significant law enforcement organizations: the Oregon Coalition of Police and Sheriffs (ORCOPS) and the Peace Officers Research Association of California (PORAC). The huge tobacco and alcohol businesses are among the members of the Coalition for Cannabis Policy, Education, and Regulation (CPEAR), which made this endorsement announcement.

The bill, known as the STATES 2.0 Act, has gained backing from prominent lawmakers, including Representative Dave Joyce, the primary sponsor. Joyce, a former prosecutor, expressed gratitude toward the law enforcement associations for their support, emphasizing the inefficiency and counterproductive nature of forcing officers to navigate conflicting state and federal cannabis laws. He highlighted that this bill would resolve these discrepancies, allowing law enforcement to better focus on public-safety and community-specific needs.

Other sponsors of the bill include Representatives Brian Mast, Troy Carter, Lori Chavez-DeRemer and Earl Blumenauer. The proposed legislation seeks to amend the CSA, thereby decriminalizing federal offenses for individuals complying with state marijuana laws and those of Indian tribes. It also aims to authorize interstate cannabis commerce and proposes a tax on marijuana to support enforcement and regulation efforts.

Brian Marvel, president of PORAC, praised the STATES 2.0 Act, noting its balance between federal oversight and state autonomy. He emphasized that while state-level legalization does not eliminate illegal markets, the act would help law enforcement target those markets more effectively. This would enable understaffed and underfunded agencies to allocate resources toward more serious crimes and illegal substances.

ORCOPS president Aaron Schmautz underscored the importance of state and federal cooperation in ensuring laws and policies achieve their intended outcomes. He highlighted the longstanding disconnect between federal marijuana regulations and state legalization efforts, affirming that the STATES 2.0 Act addresses this issue and promotes public safety and responsible marijuana policies nationwide.

Additionally, the bill includes provisions to remove cannabis sales subject to state regulation from Section 280E of the IRS code, which now prohibits the industry from claiming federal tax deductions that are available to other markets. Following the bill’s passage, the attorney general would have six months to complete a rule modifying the CSA to exempt states and tribes from the federal government’s prohibition on cannabis use.

Former Representative Greg Walden, cochair of CPEAR, emphasized the bill’s respect for state rights and its potential to resolve conflicts arising from outdated federal policies. Walden, whose views on cannabis policy evolved during his time in Congress, now advocates for aligning federal laws with state regulations, reflecting the will of voters and supporting law enforcement.

The executive director of CPEAR, Andrew Freedman, praised the STATES Act for encouraging reasonable drug-policy reform and coordinating federal policy with state initiatives. He emphasized the necessity of laws that safeguard children, improve traffic safety, fight addiction and honor local marijuana laws.

Additionally, CPEAR emphasized a recent survey that found more than 60% of Republicans are in favor of congressional legislation that preserves states’ autonomy to enact cannabis regulations. The bipartisan appeal of the STATES 2.0 Act is highlighted by this broad support.

The momentum in favor of federal marijuana policy reform is growing, and marijuana companies such as Curaleaf Holdings Inc. (CSE: CURA) (OTCQX: CURLF) can believe that change is likely to come sooner rather than later.

Curaleaf Holdings Inc. (CURLF), closed Monday's trading session at $4.49, off by 3.2328%, on 311,688 volume. The average volume for the last 3 months is 15.922M and the stock's 52-week low/high is $2.51/$6.40.

Freeport-McMoRan Inc. (FCX)

MarketClub Analysis, The Street, Schaeffer's, InvestorPlace, Kiplinger Today, SmarTrend Newsletters, StocksEarning, MarketBeat, Barchart, StreetAuthority Daily, Investopedia, Trades Of The Day, StreetInsider, TopStockAnalysts, Money Morning, QualityStocks, Daily Trade Alert, Zacks, Louis Navellier, VectorVest, Trading Tips, Trading Markets, Marketbeat.com, StockEarnings, The Growth Stock Wire, Top Pros' Top Picks, ProfitableTrading, Daily Wealth, The Wealth Report, The Online Investor, DividendStocks, TheStockAdvisors, All about trends, StreetAlerts, Wall Street Elite, Streetwise Reports, Stansberry Research, TradingMarkets, Leeb's Market Forecast, Early Bird, Market FN, Investors Alley, Dividend Opportunities, INO.com Market Report, TheStockAdvisor, Money Wealth Matters, InvestmentHouse, Investor Guide, StockTwits, Cabot Wealth, Investment House, Wealth Insider Alert, Trading Concepts, Options Trader Elite, The Best Newsletters, Market Intelligence Center Alert, Money and Markets, InvestorGuide, Wealth Daily, INO Market Report, Energy and Capital, AnotherWinningTrade, Bourbon and Bayonets, Trade of the Week, Buttonwood Research, Investing Signal, Wyatt Investment Research, Darwin Investing Network, The Motley Fool, Wall Street Daily, Investors Underground, Market Authority, Profit Confidential, Wealthpire Inc., MarketWatch, Super Stock Investor, Street Insider, MiningNewsWire, TradingAuthority Daily, Stock Research Newsletter, Inside Trading, Investor Update, Uncommon Wisdom, InvestorsUnderground, AllPennyStocks, InvestorIntel, Daily Markets, WStreet Market Commentary, CNBC Breaking News, Weekly Wizards, 24/7 Trader, Rick Saddler, FNNO Newsletters, FreeRealTime, Normandy Investment Research, TradersPro, FeedBlitz, Dynamic Wealth Report, SmallCapVoice, The Tycoon Report, StreetAuthority Investor Update, Inside Investing Daily, Weekly Market Strategies, Investiv, Pennybuster, Investing Daily, BUYINS.NET, Insider Wealth Alert, Stockhouse, Investment U, Profits Run, Greenbackers, ChartAdvisor, Oakshire Financial, Chaikin PowerFeed, Market Intelligence Center, Stock Barometer, Daily Profit, Navellier Growth, Earnings360, Forbes, Hit and Run Candle Sticks, Average Joe Options, The Stock Dork, Penny Sleuth, StreetAuthority Financial, Super Stock Picker, Taipan Daily, Terry's Tips, StockRockandRoll, The Night Owl, StockMarketWatch, The Street Report, Tim Bohen, Trader Prep, Traders.com, Trading with Larry Benedict, TradingPub, The Daily Market Alert, PowerRatings Stocks, Investor News, Investors Daily Edge, Jason Bond, MarketTamer, MicroCap Gems, Stocks To Watch, Penny Stock Buzz, InsiderTrades, Schaeffer’s, Shah's Insights & Indictments, SmallCap Network, Smart Investing Society, Stock Beast, StockLockandLoad and Milestone Capital Growth Portfolio reported earlier on Freeport-McMoRan Inc. (FCX), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In the last 12 months, the price of gold has risen by more than 20% while that of oil has increased by 15%. Investors of the precious metal are currently having a good run, with gold severing its ties with interest rates in the United States to trade at new highs.

As of Tuesday this week, U.S. gold futures were trading at $2,356.50 per ounce while the price of spot gold stood at $2,357.4 an ounce. Earlier this month, the precious metal had risen to a near one-month high, its performance being bolstered by lower treasury yields and a weakening dollar.

During that period, data showed that consumer prices in the United States were less than expected for April, which increased chances of the Fed reducing rates of interest. U.S. gold futures for June delivery hit $2,394.90 an ounce while spot gold rose by more than 1% to reach $2,386.60 an ounce.

Meanwhile, the price of oil has been increasing ahead of the upcoming meeting of the Organization of the Petroleum Exporting countries (OPEC) and its Russian allies. This comes at a time when global oil markets are on high alert as tensions in the oil-rich regions of the Middle East continue to worsen.

Airstrikes by the Israeli government on Rafah, a city in southern Gaza, has triggered widespread condemnation globally. This geopolitical situation together with expectations that OPEC’s production cuts will continue and American demand will increase in the summer bolstered the price of Brent crude to a little more than $84 a barrel.

One expert believes that the price increases of these commodities are a sign of imminent inflation. This is backed by a survey by the Federal Reserve, which found that inflation continued to increase as companies grew more cynical about the future amid reducing consumer demand.

The significant increase in the price of gold has primarily been driven by strong demand from central banks, particularly in China, Turkey and India, which have risen to unprecedented levels since 2022. Gold demand from China points to the country’s desire to decrease exposure to the U.S. dollar. Anxiety in the country’s property market has also bolstered demand for gold from retail investors in China, which is further supporting the price.

TD Securities’ head of commodity strategies, Bart Melek, stated that the entity had observed a reduction in yield curve rates and a drop in the dollar index as gold came off a correction and began performing well again. Melek noted that the Fed’s ambiguous monetary policy could keep the precious metal from performing even better during this period, however. This possibility may not be of much concern as gold extractors such as Freeport-McMoRan Inc. (NYSE: FCX) are aware that the general fundamentals suggest that gold’s price will keep climbing as the years go by.

Freeport-McMoRan Inc. (FCX), closed Monday's trading session at $52.04, off by 1.3086%, on 10,249,413 volume. The average volume for the last 3 months is 10.706M and the stock's 52-week low/high is $32.825/$55.235.

Coinbase Global Inc. (COIN)

Schaeffer's, InvestorPlace, The Street, MarketClub Analysis, QualityStocks, Prfmonline, Zacks, MarketBeat, Greenbackers, Early Bird, StockEarnings, Kiplinger Today, INO Market Report, Investopedia, SmallCapVoice, OTCPicks, The Online Investor, Ceocast News, The Wealth Report, CoolPennyStocks, HotOTC, InsiderTrades, Daily Trade Alert, StocksEarning, Trades Of The Day, StockEgg, Penny Invest, Stock Stars, Stock Rich, CryptoCurrencyWire, FreeRealTime, Top Pros' Top Picks, TradersPro, BestOtc, CNBC Breaking News, Top Gun, The Stock Psycho, Investors Underground, StockHotTips, HotShotStocks, BullRally, Wealth Daily, Energy and Capital, MadPennyStocks, BillionDollarClub, Jeff Bishop, Today's Financial News, Summa Money, StockRich, Smartmoneytrading, PennyStockVille, Stockpalooza, PennyTrader Publisher, Profit Confidential, bullseyeoptiontrading, PennyInvest, FeedBlitz, Cabot Wealth, AlphaShark Trading, Atomic Trades, Early Investing, Dawn Report, Blaque Capital Stocks, BloomMoney, Eagle Financial Publications, Dynamic Wealth Report, CRWEWallStreet, Stock Analyzer, wyatt research newsletter, WiseAlerts, wealthmintrplus, Wealth Whisperer, TradingPub, Trading with Larry Benedict, TipRanks, StockMister, Penny Stock Finder, Stock Fortune Teller, Green Chip Stocks, Standout Stocks, Round Up the Bulls, Pennybuster, Penny Stock Rumble, AllPennyStocks, Momentum Traders, MicrocapVoice, Louis Navellier, InvestorsUnderground and Stock Traders Chat reported earlier on Coinbase Global Inc. (COIN), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

In February, a Binance trader by the handle “doomxbt” uncovered a significant issue when they observed losses amounting to $70,000 due to suspicious activity. The attacker had deposited these stolen funds into SideShift, a crypto exchange driven by artificial intelligence.

It was revealed this week that the culprit might be identified, thanks to a phony Aggr app extension that was sold on the Google Chrome store. The fake Aggr software was made to collect all website cookies from users, in contrast to the real Aggr app, which provides expert trading tools, including on-chain liquidation trackers. This made it possible for hackers to recover access keys and passwords, especially for accounts on Binance.

Following its listing on the Chrome Store, the hackers launched a vigorous social media campaign to drive downloads of this fake Aggr app. They used a network of influencers, a strategy known as “shilling,” to advertise the dangerous software. The influencers convinced consumers that the product was necessary by flooding social-media feeds with trading lingo.

In this situation, the influencers seemingly disregarded the well-known crypto mantra “do your own research” (DYOR). It remains unclear whether the promoters were aware that the fake Aggr app compromised user security or if they were simply profiting from the attack.

The recent episode is part of a broader pattern of comparable attacks that make use of Chrome extensions. For example, another trader lost more than $800,000 in crypto last month as a result of utilizing two rogue Chrome browser extensions. The extensions, named Simple Game and Sync test BETA (colorful), were suspected to contain keyloggers intended to target wallet extension apps. A keylogger is a kind of malicious software that tracks every keystroke a user makes so the person who installed it may access the data.

The problem arose after a Chrome update forced the user to log out of all their tabs and extensions. After a Windows update caused the system to restart, the user unintentionally exposed their data by reentering their credentials, which included seed phrases for crypto wallets.

Afterward, funds were transmitted to the Gate.io and MEXC exchanges using the malicious extension. Investigations showed that Simple Game monitored tab activity, while Sync test BETA (colorful) was the keylogger that transferred data to an external PHP script. The harmful nature of the extensions was eventually detected by the user, despite the browser appearing to be functioning normally.

These incidents highlight the persistent threat posed by rogue Chrome extensions in the digital asset world. Users are strongly advised to practice DYOR and thoroughly verify any application before downloading it to better protect themselves from such cyber threats.

Major entities such as Coinbase Global Inc. (NASDAQ: COIN) in the crypto industry are likely to keep monitoring how hackers evolve and also update their security systems to adapt to those evolving threats.

Coinbase Global Inc. (COIN), closed Monday's trading session at $231.39, up 2.4212%, on 7,333,118 volume. The average volume for the last 3 months is 6.909M and the stock's 52-week low/high is $46.43/$283.48.

Salesforce Inc. (CRM)

The Street, InvestorPlace, Kiplinger Today, Schaeffer's, MarketClub Analysis, Investopedia, MarketBeat, All about trends, StreetInsider, Zacks, StocksEarning, The Online Investor, Trades Of The Day, StreetAuthority Daily, Daily Trade Alert, Barchart, Market Intelligence Center Alert, Early Bird, StockEarnings, FreeRealTime, Money Morning, INO.com Market Report, Cabot Wealth, Marketbeat.com, Wealth Insider Alert, TipRanks, Money and Markets, Louis Navellier, Street Insider, TopStockAnalysts, internetnews, Daily Wealth, ProfitableTrading, SmarTrend Newsletters, Money Wealth Matters, GorillaTrades, Top Pros' Top Picks, PROFIT CONFIDENTIAL, InvestmentHouse, Stansberry Research, The Motley Fool, AllPennyStocks, Wyatt Investment Research, Investors Alley, TradingMarkets, Super Stock Investor, Trading Concepts, Daily Profit, FeedBlitz, The Wealth Report, StrategicTechInvestor, InvestorGuide, Uncommon Wisdom, CNBC Breaking News, Darwin Investing Network, Investment House, MarketWatch, TheStockAdvisors, Stock Tips Network, The Night Owl, Millennium-Traders, YOLOTraderAlerts, Stockhouse, INO Market Report, QualityStocks, Insider Wealth Alert, The Trading Report, IT News Daily, Investing Daily, Trading Markets, InvestorsObserver Team, FNNO Newsletters, Market Intelligence Center, Greenbackers, internet, The Stock Enthusiast, The Best Newsletters, Investment U, The Street Report, StockTwits, Daily Markets, Wall Street Daily, MarketTamer, Trading Tips, SmallCapVoice, Dynamic Wealth Report, Dividend Opportunities, SureMoney, CustomerService, Earnings360, Wealth Daily, The Wall Street Transcript, Investor Update, Investor Guide, The Weekly Options Trader, BUYINS.NET, Jim Cramer, Inside Trading, Investing Signal, Eagle Financial Publications, The Growth Stock Wire, Todd Horwitz, WStreet Market Commentary, Bellwether Report, Options Elite, Smart Investing Society, SmartMoneyTrading, The Stock Dork, Trading with Larry Benedict, equities Canada, InsiderTrades, TheOptionSpecialist, TheStockAdvisor, TradingAuthority Daily, DividendStocks, Buttonwood Research, Equities.com, Chaikin Analytics, Hit and Run Candle Sticks, Inside Investing Daily, PennyOmega, Average Joe Options, Chaikin PowerFeed, Brainy Brands Company Alerts, Damn Good Penny Picks, Traders For Cash Flow, StockMarketWatch, StockOnion, Stocks That Move, Stocks To Watch, Stocktwiter, StreetAuthority Financial, TheTradingReport, Penny Pick Finders, Trader Prep, Rick Saddler, TradersPro, Trading For Keeps, TradingTips, Vantage Wire, Wall Street Greek, Wallstreetlivechat, Wealthpire Inc., Trade of the Week, 24/7 Trader, Investiv, InvestorsUnderground, iStockAnalyst, Jon Markman's Pivotal Point, Leeb's Market Forecast, Market Authority, Market FN, SmallCap Network, OTCtipReporter, SiliconValley, Penny Stock Buzz and PennyStockProphet reported earlier on Salesforce Inc. (CRM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.

A new survey has determined that few individuals regularly use hyped artificial intelligence (AI) tools such as ChatGPT. The investigators surveyed 12,000 individuals in six countries, including the United Kingdom, Japan, France, Denmark, Argentina and the United States. Of the total number surveyed, only 2% of respondents revealed that they used such products on a daily basis.

The survey was carried out by Oxford University and the Reuters Institute. In their report, the investigators stated that young individuals were going against the trend, with 18- to 24-year olds being eager adopters of this technology.

The lead author of the study, Dr. Richard Fletcher, stated in an interview that there was a mismatch between the public interest in artificial intelligence and the hype around it.

For their research, the investigators looked at views on generative artificial intelligence products, which are a new generation of tools that can respond to text prompts with answers as well as audio, images and video. Generative artificial intelligence came onto the scene in 2022 when ChatGPT was launched. The attention the chatbot garnered triggered a competition among technology companies that have since been injecting billions of dollars into developing their own AI products.

This study shows that despite all the attention and money been directed to generative artificial intelligence, it hasn’t translated to actual use by the general population. Fletcher noted that large chunks of the public weren’t particularly interested in AI, with 30% of individuals in the United Kingdom revealing that they hadn’t heard of any popular products.

The investigators also determined that most individuals expected generative artificial intelligence to have a huge impact on the society in the coming years, particularly for science, media and news. Most individuals also admitted to believing that these products would make their own lives better. Conversely, when asked if these tools would make the society as a whole worse or better, many individuals gave pessimistic views.

In the report, Fletcher noted that the fears and hopes of individuals when it came to artificial intelligence varied a lot, depending on the sector one was involved in. He explained that generally, individuals were optimistic about the use of artificial intelligence in healthcare and science but a bit pessimistic when it came to the technology’s use in journalism and news.

Additionally, some were worried about the technology’s impact on job security. Fletcher then added that the study was important because it highlighted the need to apply nuance to discussions on artificial intelligence.

Companies such as Salesforce Inc. (NYSE: CRM) may be unfazed by the talk of the current limited use of novel AI technologies because it is common for adoption to be initially slow before reaching a tipping point and accelerating to become commonplace in almost all industries.

Salesforce Inc. (CRM), closed Monday's trading session at $236.62, up 0.9298754%, on 19,962,737 volume. The average volume for the last 3 months is 56,593 and the stock's 52-week low/high is $193.68/$318.715.

The QualityStocks Company Corner

Nutriband Inc. (NASDAQ: NTRB)

The QualityStocks Daily Newsletter would like to spotlightFathom Nutriband Inc. (NASDAQ: NTRB) .

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, is reporting its first-quarter 2024 revenues. According to the report, the company saw revenues of $408,532 while also strengthening its balance sheet with the completion of an $8.4 million private placement involving existing and new shareholders; shares for the placement were offered at $4 per share. Nutriband also reported a cash position of $8,347,739. In the report, the company observed that it been focused on using penetration pricing to gain a foothold. "Meanwhile in Q1, the company has made further advancements in its development of AVERSA, and it is maintaining a target of Q1 2025 for its NDA filing with the FDA," the press release stated. "The company recently updated shareholders about its development pathway for AVERSA Fentanyl reminding shareholders that its NDA will be primarily based on a single phase 1 Human Abuse Potential clinical study with no phase 2 or phase 3 clinical trials required prior to submission. AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. AVERSA Fentanyl is estimated to have the potential to reach peak annual sales of $80–$200 million, according to a market analysis report from Health Advances. AVERSA Buprenorphine, which is the company's second application for AVERSA, has been further estimated to reach peak annual sales of up to $130 million."

To view the full press release, visit https://ibn.fm/ggwEu

Nutriband Inc. (NASDAQ: NTRB) is engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s AVERSA™ technology can be incorporated into any transdermal patch and includes aversive agents to prevent abuse, diversion, misuse and accidental exposure to drugs with abuse potential, specifically opioids.

AVERSA technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, such as fentanyl, while making sure that these drugs remain accessible to patients who need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, Canada, Mexico and Australia.

The company’s business model is to apply its transdermal technology to existing FDA-approved drugs with a goal of improving safety, efficacy and patient comfort while qualifying for a limited-development regulatory pathway that reduces the number of clinical trials required for approval of new drugs.

Nutriband has three subsidiaries, including 4P Therapeutics, its clinical and regulatory subsidiary; Pocono Pharmaceutical, a contract manufacturer for a wide range of clients; and Active Intelligence, a developer of sports recovery products. This ownership of manufacturing and clinical development capabilities drastically reduces costs for AVERSA and other technologies.

In April 2024, Nutriband announced that the company had been engaged by and received a first order from Fit For Life Group, a major brand license holder. A fully executed supplier agreement is expected to follow. Nutriband’s wholly owned Active Intelligence subsidiary will act as manufacturer.

The company is headquartered in Orlando, Florida.

Products

Nutriband’s lead product candidate is AVERSA Fentanyl, an abuse-deterrent fentanyl transdermal patch. The company announced in March 2024 that it will submit a New Drug Application to the U.S. Food and Drug Administration seeking approval to market AVERSA Fentanyl.

Nutriband has partnered with Kindeva Drug Delivery, a leading global contract development and manufacturing organization, to incorporate Nutriband’s AVERSA abuse-deterrent transdermal technology into Kindeva’s FDA-approved transdermal fentanyl patch system. Because Nutriband’s abuse-deterrent technology is incorporated into the fentanyl patch but is physically separate from and does not come in contact with the drug layer, the clinical trials typically needed to demonstrate safety and efficacy for a new drug formulation would not be required.

AVERSA Fentanyl has the potential to be the first and only abuse deterrent patch approved anywhere in the world. The company plans to seek an expedited review by the FDA, as has been granted for certain abuse-deterrent oral opioid products, which shortens the regulatory review period to six months from the conventional 10-month FDA review cycle for NDAs.

Nutriband’s AVERSA product development pipeline also includes abuse deterrent versions of currently approved and marketed transdermal patches containing buprenorphine, an opioid used to treat opioid use disorder, and methylphenidate, a central nervous system stimulant used in the treatment of attention deficit hyperactivity disorder (ADHD). Both are labeled with FDA-required warnings for the risk of abuse and misuse, as well as warnings against accidental exposure.

Market Opportunity

Nutriband cites a market analysis report from Boston-based Health Advances, a healthcare and life sciences consulting firm. According to the report, upon FDA approval, AVERSA Fentanyl has the potential to reach peak annual sales of $200 million in the U.S.

The company further states that, should non-abuse-deterrent transdermal fentanyl products lose FDA marketing approval, AVERSA Fentanyl would have greater pricing flexibility and would have the potential to generate more than $500 million in annual revenue.

Management Team

Gareth Sheridan is Co-Founder and CEO of Nutriband. He was Ireland’s ‘Young Entrepreneur of the Year’ in 2014 for establishing Nutriband. He has worked as a Business Mentor with 100 Minds, a social enterprise that brings together some of Ireland’s top college students and connects them with a cause to achieve large charitable goals. He received a B.Sc. in Business and Management from Dublin Institute of Technology.

Serguei Melnik is Co-Founder and President of Nutriband. He has been involved in general business consulting for companies in the U.S. financial markets and setting up legal and financial frameworks for operations of foreign companies in the U.S. He previously was the COO of Florida-based Asconi Corporation. He also was a lawyer in the Department of Foreign Affairs, JSC Bank “Inteprinzbanca,” in Chisinau, Moldova, and prior to that practiced law in Moldova. He is fluent in four languages.

Jeff Patrick, Pharm.D., is Chief Scientific Officer of Nutriband. He currently serves as Director of the Drug Development Institute at the Ohio State University Comprehensive Cancer Center. His prior roles included Global Vice President at Mallinckrodt Pharmaceuticals Inc.; and roles at Dyax, Myogen/Gilead, Actelion and Sanofi-Synthelabo Inc. He was a clinical pharmacist at the University of Tennessee Medical Center and a clinical assistant professor of pharmacy at the University of Tennessee College of Pharmacy.

Gerald Goodman is CFO of Nutriband. He is a certified public accountant with his own firm, Gerald Goodman CPA. He also practiced with Madsen & Associates, CPAs, and was a partner in the accounting firm of Wiener, Goodman & Company. He is also a director of Lifestyle Medical Network Inc., which provides management services to healthcare providers. He is a graduate of Pennsylvania State University, where he received a bachelor’s degree in accounting.

Nutriband Inc. (NASDAQ: NTRB), closed Monday's trading session at $6.16, up 13.0275%, on 136,983 volume. The average volume for the last 3 months is 60,868 and the stock's 52-week low/high is $1.53/$6.75.

Recent News

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF)

The QualityStocks Daily Newsletter would like to spotlight First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) .

ExxonMobil is receiving criticism from its environment, sustainability and governance ("ESG") activist investors despite delivering exceptional results over the last quarter. ESG has become a major trend in financial circles in recent years amid national and global efforts to transition from fossil fuels and protect communities as well as the environment. Ecofriendly investors typically use ESG considerations to determine which companies to invest in to ensure sustainability-related sectors receive the funding they need to grow. Companies such as ExxonMobil with deep ties to the fossil-fuel industry are obligated to ensure their operations are as green and sustainable as possible while they work to eliminate fossil fuels from their supply chains. In a letter sent to Glass Lewis on May 15, 2024, ExxonMobil requested the withdrawal of the recommendation and noted that Glass Lewis had a conflict of interest in the matter. For entities that have integrated ESG into their entire operations, such as First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF), the court battles that the ExxonMobil board is facing may never happen since any shareholder value delivered will possibly have ESG embedded in it.

First Tellurium Corp. (CSE: FTEL) (OTCQB: FSTTF) is committed to exploring for and providing essential and critical metals, including tellurium, gold, silver, copper and tungsten, for North American markets. This objective is anchored by the company’s Deer Horn tellurium-gold-silver-copper project in British Columbia, Canada, and further enhanced by its property option on the Klondike tellurium-gold prospect located in Colorado, USA.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in indigenous territory with sustainable exploration potential.

The company is headquartered in Vancouver, British Columbia.

Tellurium and the Green Energy Revolution

Tellurium has a key role to play in the ongoing green energy revolution. It is widely used in the manufacturing of photovoltaic cells for solar panels.

Despite this utility, ongoing trade tensions between China and the U.S. create implications for both tellurium and the production of cadmium-tellurium solar cells. Earlier this year, China announced plans to restrict exports of critical metals gallium and germanium, both essential for the production of semiconductors. For reference, China produces around 80% of the world’s gallium and approximately 60% of the world’s germanium.

China’s recent trade restrictions amplify the fragility of the North American tellurium supply, as the Asian nation currently produces about 60% of the world’s tellurium. This sustained supply vulnerability is why First Solar, the United States’ largest solar panel producer, set up a worldwide search for tellurium deposits in the mid-2000s.

“In North America alone, our understanding is that First Solar looked at over a hundred tellurium properties,” First Tellurium CEO Tyrone Docherty stated in a news release. “Their number one property by far, which they acquired, was the Colorado Klondike which we now control.”

The U.S. is now looking to secure safe, domestic sources of tellurium and many other critical metals to pre-empt potential shortages. The Biden administration has instituted a stream of policies, particularly the U.S. Inflation Reduction Act, to source solar components from North America and other “friendly” jurisdictions.

As the only junior mining company in the world focused on tellurium exploration, First Tellurium is ahead of the curve in capitalizing on these initiatives to establish strategic, domestic supplies of key resources for solar panel manufacturers.

First Tellurium’s ESG Initiatives

Through its exploration and partnerships with Fenix Advanced Materials, Cheona Metals and IRMA, First Tellurium strives to generate a measurable, beneficial social or environmental impact alongside a financial return. The company conducts a diversified search for metals, working in alliance with indigenous peoples, NGOs, governments and leading metals buyers. First Tellurium believes this is the future of mineral exploration — generating revenue by exploring responsibly and leveraging diverse partnerships.

First Tellurium proudly adheres to, and supports, the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and, in particular, the fundamental proposition of free, prior and informed consent.

 

Projects

Deer Horn Tellurium-Gold-Silver-Copper Project

Deer Horn is located on 51.33 square kilometers (km) in west-central British Columbia, 36 km south of the prolific Huckleberry copper-molybdenum mine and 135 km southwest of the community of Burns Lake. It is one of few significant tellurium discoveries outside Asia and includes a 2.4 km-long vein system of high-grade gold, silver and tellurium, as well as broader zones of bulk-tonnage gold, silver and tellurium mineralization. The company completed a positive Preliminary Economic Estimate and has begun permitting for a 10,000-tonne bulk sample program to advance the project toward mine feasibility. It is North America’s only silver-gold-tellurium property with an NI 43-101 compliant tellurium resource, and it hosts a number of other mineralized targets and zone containing critical metals such as copper, tungsten and zinc.

First Tellurium owns 50% of the property, with an option to acquire up to a 75% interest. The company has engaged Dias Geophysical of Saskatoon, Saskatchewan, to conduct induced polarization (IP) geophysics on the Deer Horn Project in summer 2023. The program is designed to help develop drill targets for a subsequent drilling program.

Klondike Gold-Tellurium Project

The Klondike property is located in Saguache County, Colorado, southwest of Buena Vista in the state’s historical mining district. The company reports it has engaged Burgex Mining Consultants of Sandy, Utah, to stake additional claims around the Klondike property. The claims have been filed with the Bureau of Land Management.

Klondike demonstrates exceptional tellurium grades. Tellurium, used in high-efficiency cadmium telluride (Cd-Te) solar panels, next-generation lithium-ion batteries and thermoelectric devices to change heat into energy, is an essential element for the world’s transition to green energy.

The Klondike property was a top tellurium prospect owned previously by First Solar Inc., one of the world’s largest solar panel producers. First Solar terminated its worldwide raw materials exploration program in 2012 and sold the property to Colorado Klondike LLC, which optioned the project to First Tellurium. Colorado Klondike, led by First Solar’s former Exploration Manager in North America, is managing the upcoming exploration program.

The Colorado Geological Survey (CGS), in partnership with the Colorado School of Mines, reported on First Solar’s exploration at Klondike in 2015, noting: “Surface sampling by First Solar, Inc. in 2006 found very high tellurium grades of up to 3.3% (33,000 ppm), along with locally high gold grades. Tellurium grades at Klondike were the highest encountered in the company’s nationwide exploration program.”

Market Outlook

First Tellurium in spring 2023 referenced recent forecasts by the International Energy Agency (IEA) pointing to rapid growth in solar photovoltaic (solar PV) deployment worldwide. According to the agency, solar PV installations will generate more power by 2027 than any other energy source, including coal, natural gas and hydro. To meet this demand, consumption of both silver and tellurium, key components of solar panels, is expected to surge in coming years.

Chen Lin, founder of Lin Asset Management, has written in his investment newsletter for clients that solar PV is now the largest industrial usage of silver. He said that in 2022 solar PV production used about 12% of total silver demand, or about 120 million ounces of silver. Lin expects this number to rise dramatically in the coming years, and that is likely to lead to silver supply deficits for decades to come.

Lin points out that solar power is now the cheapest source of energy in many parts of the world and that all forecasts point to dramatic expansion of solar PV in the coming two decades. Conservative estimates forecast 300 gigawatts of solar PV production by 2027, up from the current level of about 200 gigawatts.

Management Team

Tyrone Docherty is President, Director and CEO of First Tellurium Corp. He previously served as President and CEO of Quinto Mining Inc., taking over when it had a market cap of $4 million. With limited resources in a difficult market environment, he raised more than $30 million and advanced Quinto’s Quebec iron ore property to a viable project. Quinto later sold for $175 million, with Quinto management taking shares of the purchaser, Consolidated Thompson Iron Mines, amounting to approximately 20-21% of that company. Consolidated Thompson Iron Mines sold two years later for $4.9 billion, giving the former Quinto team an enterprise value of approximately $1 billion. From 2012 to 2018, Mr. Docherty was Director and Chairman of Mason Graphite Inc. He has worked in the financial and minerals markets for more than 30 years.

Tony Fogarassy, M.Sc. LL.M., is Chairman of First Tellurium Corp. He is a lawyer and a geologist. His extensive legal and technical expertise includes minerals, oil and gas, coal and renewable energy projects and environmental and aboriginal/indigenous law in North America, Africa and Asia. He graduated as gold medalist in geological sciences from the University of British Columbia and in law from the London School of Economics.

First Tellurium Corp. (OTCQB: FSTTF), closed Monday's trading session at $0.081, up 2.9225%, on 232,100 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $6.75/$.

Recent News

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF)

The QualityStocks Daily Newsletter would like to spotlight Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF).

Emperor Metals announced an ambitious initial 2024 fully funded 8,000-meter drill program and 8,000-meter historical core assaying at its Duquesne West Gold Project, set to commence this month

Emperor is fully funded with approximately $4 million in working capital and will advance the Duquesne West project towards an updated mineral resource expected by Q1, 2025

Company receives $1 Million From Industry Legend – Rob McEwen, Founder of Goldcorp

Emperor Metals (CSE: AUOZ) (OTCQB: EMAUF) (FRA: 9NH), an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec, recently announced that it is continuing to strengthen its position in gold exploration through recent advancements. These efforts show the company's commitment to expanding its resource base and enhancing shareholder value.

Emperor Metals Inc. (CSE: AUOZ) (FRA:9NH) (OTCQB: EMAUF) is an advanced stage gold exploration company focused on proving and developing the substantial resource potential of its flagship Duquesne West Gold Project located in the Tier 1 district of the Southern Abitibi Greenstone belt of Rouyn-Noranda, Quebec. The Project has a 2011 historical mineral resource estimate of 727,000 ounces of Au at 5.42 g/t and an average thickness of 5.71 m*.

In 2023, with the use of AI (Artificial Intelligence), Emperor Metals created the first ever 3D mineralized and geological model, which illuminated the potential to add significant ounces to this deposit. Using these models, Emperor’s had a very successful 2023 drilling campaign of 8,579 m. In addition to laterally extending high grade zones by intercepting grades of 15.8 g/t Au over 10.8 meters, Emperor encountered intercepts of lower grade bulk tonnage in the host rocks (1.69 g/t Au over 25 m). This led to envisioning a different strategy of exploration and the revelation that a conceptual open-pit potentially overlies this high-grade gold deposit. Historic core sampling began (2,500 m) for discovering overlooked lower grade gold in the host rock around the high-grade lenses. Lower grade bulk tonnage gold improves the open-pit economics by reducing stripping ratios and adding overlooked incremental ounces for open pit mining.

Emperor Metals is set to begin a fully funded Phase II 8,000 m drilling program in May 2024. The company also plans on assaying an additional 8,000 m of historic core within the open pit model. Emperor is working toward producing an updated NI 43-101 Mineral Resource Estimate by Q1 2025.

The company is led by a dynamic group of resource sector professionals who have a strong record of success in evaluating and advancing mining projects from exploration through to production, attracting capital and overcoming adversity to deliver exceptional shareholder value.

Project

Emperor Metals has an option to earn 100% ownership of the Duquesne West Gold Project, a mineral claim package comprising 38 claims covering approximately 1,389 ha (3,432 acres) in Quebec.

The Duquesne West Gold Property is located 32 kilometers northwest of the city of Rouyn-Noranda and 10 kilometers east of the town of Duparquet. The property lies within the historic Duparquet gold mining camp in the southern portion of the Abitibi Greenstone Belt in the Superior Province.

Emperor is targeting the potential multimillion-ounce resource in a combination of conceptual open pit and underground mining scenarios. A Phase I drill campaign and historical core sampling program was completed in 2023, which included resource confirmation and exploration drilling, focusing on delineating and growing the resource toward development.

The property hosts a historical inferred mineral resource estimate of 727,000 ounces of gold at a grade of 5.42 grams per ton (g/t) and average stope thickness of 5.71 m. The mineral resource estimate predates modern Canadian Institute of Mining guidelines, and a Qualified Person on behalf of Emperor Metals has not reviewed or verified the mineral resource estimate. Therefore, it is considered historical in nature and is reported solely to provide an indication of the magnitude of mineralization that could be present on the property. The gold system remains open for resource identification and expansion.

Reinterpretation of the existing geological model was created using artificial intelligence and machine learning. This AI model shows the opportunity for additional discovery of ounces by revealing gold trends unknown to previous workers and the potential to expand the resource along significant gold-endowed structural zones. Multiple scenarios exist to expand additional resources, which include:

  • Underground High-Grade Gold
  • Open Pit Bulk Tonnage Gold
  • Underground Bulk Tonnage Gold

The Duquesne West-Ottoman property straddles the Porcupine-Destor gold localizing fault several kilometers east of the town of Duparquet. A number of previous drill campaigns have outlined an inferred resource of 4.17 million tons grading 5.42 g/t of gold (cut) or 6.36 g/t (uncut), as reported in the NI 43-101 report titled “Technical Report and Mineral Resource Estimate Update for the Duquesne-Ottoman Property, Quebec, Canada.”

Emperor Metals is funded for an 8,000-meter drilling program focusing primarily on adding ounces to the current resource within and lateral to the open pit model. An additional 8,000 m of historical core sampling and assaying is included in the budget to help build incremental ounces in the open-pit environment.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, to be worth nearly $5 trillion.

The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth. This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

In May 2024, the market price of gold was approximately $2,340 per ounce.

Management Team

John Florek, P.Geol., is President, CEO and Director of Emperor Metals. He has more than 35 years of technical and senior management experience with major and junior mining companies, including roles as founder, vice president and director. He has helped identify and develop significant asset value for mines and exploration projects from grass roots through development. He has worked for several major mineral producers, including BHP, Placer Dome, Barrick, Teck and Detour Gold/Kirkland Lake Gold/Agnico Eagle.

Sean Mager is CFO and Director of Emperor Metals. He has worked more than 30 years in the mining sector, including extensive experience in corporate development, stakeholder relations, regulatory, financial and operations.

Alex Horsley is Head of Corporate Development and Director of Emperor Metals. He has more than 20 years of experience in the mining sector and capital markets with a focus on finance, marketing, management, corporate development and communications. He is founder and former CEO of Emperor Metals. He has assisted in raising more than C$40 million for exploration and development mining companies.

*Power-Fardy and Breede, 2011. The Mineral Resource Estimate (MRE) constructed in 2011 is considered historical in nature as it was constructed prior to the most recent Canadian Institute of Mining and Metallurgy (CIM) standards (2014) and guidelines (2019) for mineral resources. In addition, the economic factors used to demonstrate reasonable prospects of eventual economic extraction for the MRE have changed since 2011. A qualified person has not done sufficient work to consider the MRE as current. Emperor is not treating the historical MRE as current. The reader is cautioned not to treat it, or any part of it, as a current MRE.

Emperor Metals Inc. (OTCQB: EMAUF), closed Monday's trading session at $0.0912, even for the day, on 1,098 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0597/$0.14505.

Recent News

Software Effective Solutions Corp. (OTC: SFWJ)

The QualityStocks Daily Newsletter would like to spotlight Software Effective Solutions Corp. (OTC: SFWJ).

Company calls rescheduling a "monumental decision" that signifies a significant shift in U.S. drug policy

MedCana CEO notes rescheduling "opens the door to further research, innovation and accessibility, signaling a new era of acceptance and understanding"

SFWJ remains committed to advancing the dialogue around cannabis policy and supporting initiatives that promote responsible access and use

Software Effective Solutions (d/b/a MedCana) (OTC: SFWJ) has noted a "historic milestone" as the U.S. Drug Enforcement Administration ("DEA") moves to reclassify cannabis from Schedule I to Schedule III under the Controlled Substances Act (https://cnw.fm/yNude). The company released an announcement from CEO Jose Gabriel Diaz and observed that the "monumental decision," based on recommendations from the U.S. Department of Health and Human Services, signifies a significant shift in U.S. drug policy.

The U.S. Department of Justice (DOJ) is set to begin accepting comments on a rule that would move marijuana to a lower drug classification. This historic move comes after the U.S. Department of Health and Human Services recommended that the drug be rescheduled following a directive issued by President Biden in 2022 to review the drug's current classification. At the moment, marijuana is classified as a Schedule I drug under the Controlled Substances Act. Drugs under this classification are said to have no accepted use in the medical world and a high potential for abuse. The drugs include heroin, LSD, peyote, raw opium, methaqualone and ecstasy. It is expected that since the proposed rule has a lengthy regulatory process ahead, the situation may not be concluded until after the upcoming presidential election. In the meantime, cannabis companies such as Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) will probably monitor the comments submitted to see what possible result will come out of the rulemaking process triggering cannabis rescheduling by the DEA.

Software Effective Solutions Corp. (d/b/a MedCana) (OTC: SFWJ) is a global infrastructure and holding company in the cannabis industry. MedCana currently has five companies focused on pharmaceutical cannabis production, as well a software company focused on managing processes for plant-to-patient operations. The recent acquisition of an irrigation and greenhouse technology company has rounded out MedCana’s portfolio of holdings.

MedCana’s focus is on developing clients and companies in Latin America, initially in Colombia, and partnerships with laboratories, research facilities and hospitals throughout the world. MedCana is building the technology, laboratories, growing facilities and scientific teams to provide premium pharmaceutical-grade cannabis extracts to the world.

MedCana’s goal is to be the world’s premier resource for pharmaceutical cannabis products. The company believes its advantage is its global view and reach. From initial cultivation to final product, MedCana aims to help partners produce pharmaceutical CBD and other extracts that will have no equal.

The company’s mission is to utilize its technology to partner with and develop companies that provide premium pharmaceutical-grade cannabis extracts with absolute integrity, sustainability and social responsibility. MedCana’s team of pharmaceutical scientists includes some of the most respected chemists in the world. They aim to ensure that the company’s customers and partners create premium cannabis extracts that meet the growing worldwide demand. MedCana’s software is designed to ensure traceability and quality from seed to finished product.

MedCana is headquartered in Austin, Texas, with offices in Colombia.

Production

MedCana announced in May 2023 the beginning of full-scale production of non-THC cannabis for export to Europe in response to high demand in that market. This expansion comes after the successful completion of full crop cycle testing and infrastructure development at production sites in Columbia.

The recent acquisition of the assets of Tokan Corp., a software company focused on creating an enterprise resource planning (ERP) platform for the cannabis industry, and Eko2O S.A.S., a greenhouse and irrigation engineering company, has positioned MedCana for explosive growth in the region.

As a MedCana subsidiary, Eko2O SA will increase the company’s revenue potential in Central and South America. The subsidiary specializes in the construction and distribution of greenhouses and sophisticated irrigation platforms. A positive outlook has resulted from the company’s expansion as it investigates new opportunities for greenhouse and irrigation system installations in Panama and Uruguay. These opportunities are expected to accelerate Eko2O’s development and strengthen its position as a top supplier of innovative agricultural solutions in cannabis and other sectors that are quickly moving to high technology agricultural production.

In addition, MedCana has started talks with the government in Argentina about possible incentives for beginning operations in that country as part of its ongoing worldwide development strategy. Support from the Argentinean government and the start of new operations there would greatly increase MedCana’s market share in Latin America and solidify the company’s position as the market leader in the cannabis industry.

Market Opportunity

According to a report by Grand View Research, a San Francisco-based market research and consulting company, the global cannabis extract market was valued at $3.5 billion in 2022 and is expected to expand at a CAGR of 20% from 2023 to 2030 to be worth more than $15 billion.

Growing demand for cannabis extracts, including oils and tinctures, and the increased legalization of marijuana for the treatment of different chronic ailments like arthritis, Alzheimer’s, anxiety and cancer are driving the expansion of the industry. The marijuana derivative industry is flourishing due to a greater understanding of its various medical benefits.

Management Team

Jose Gabriel Diaz is CEO of MedCana. He has successfully built, grown and sold multiple telecom companies. He was senior vice president of sales at IP Communications, a national high-speed data provider. He also founded Reallinx, a national data carrier later sold to GTT Communications. Additionally, he is currently president of the A.E.M. Business and Entrepreneurship Association in Austin, Texas.

Claudio Jiménez Cartagena, QF, Ph.D. is Chief Scientific Officer at MedCana. He joined MedCana after working with Sosteli Pharma as Technical Director and serving as a director consultant for the Corporation for Agricultural Industrial Development at the University of Antioquia in Colombia. Before that, he worked as the scientific director at the Institute of Food Science & Technology. He holds a bachelor’s degree in pharmaceutical chemistry, a master’s degree in basic biomedical sciences and a doctoral degree in Environmental Engineering from the University of Antioquia.

Julián Alberto Londoño Londoño, Ph.D., is Senior Vice President of Operations at MedCana. He previously served as general manager for the Corporation for Agricultural Industrial Development, and as Chief Scientific Officer at Sosteli Pharma in the Resource Management Department. He has developed multiple U.S. patents, and recently served as senior advisor to the Secretariat of Agriculture Development for the Government of Antioquia. He holds a doctorate in Chemical Sciences from the University of Antioquia.

Software Effective Solutions Corp. (OTC: SFWJ), closed Monday's trading session at $0.05, even for the day, on 1 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.000001/$0.09.

Recent News

Mullen Automotive Inc. (NASDAQ: MULN)

The QualityStocks Daily Newsletter would like to spotlight Mullen Automotive Inc. (MULN).

Gaining an understanding of the circadian rhythms of plants could open the door to developing a new type of clean energy, a study suggests. The research shows that we could harness the electric potential or voltage that plants create when they draw water through their roots by learning their biological clocks. Using this electric potential could lead to the creation of a new renewable energy source. Every living organism is subject to a circadian rhythm, or biological clock, that determines its biological processes through the day and night in cycles. Plants use light from the sun to conduct photosynthesis and absorb water and nutrients from the soil during the day cycle before winding down their processes during the night cycle. Harnessing the electric potential of plants would also provide a novel type of green energy to aid in the transition from fossil fuels to renewables while incentivizing the planting of new trees, essentially killing two birds with one stone. With no impact on the environment or ecosystem, this new form of green energy could offer a significantly sustainable means of generating sustainable electricity for the grid alongside solar, wind, geothermal and hydro energy. As sourcing energy from plants is further explored, entities such as Mullen Automotive Inc. (NASDAQ: MULN) will press ahead with bringing to market innovative electric vehicle models that run on green energy in order to decrease the use of fossil fuels and combat climate change.

Mullen Automotive Inc. (NASDAQ: MULN) is a Southern California-based automotive company that owns and partners with several synergistic businesses working toward the unified goal of creating clean and scalable energy solutions. Mullen has evolved over the past decade in sync with consumers and technology trends. Today, the company is working diligently to provide exciting EV options built entirely in the United States and made to fit perfectly into the American consumer’s life. Mullen strives to make EVs more accessible than ever by building an end-to-end ecosystem that takes care of all aspects of EV ownership.

Commencement of Trading on Nasdaq

On November 5, 2021, Mullen announced its commencement of trading on the Nasdaq Capital Market.

“Today is a monumental day for Mullen Automotive. I am especially proud of our team, investors and all who have believed in Mullen and taken us to this point as a publicly traded company on the Nasdaq Capital Market,” David Michery, CEO and Chairman of Mullen Automotive, stated in the news release. “Trading on Nasdaq now opens us up to new investors, both institutional and retail shareholders, and broadens our awareness and company profile, while increasing awareness of Mullen and our technology platform and opening new opportunities in EV and beyond. The road ahead has never been brighter for Mullen, and I am proud to lead us into the future.”

The milestone came in the wake of the company’s stock-for-stock merger with Net Element Inc.

The Mullen FIVE

The Mullen FIVE EV Crossover, debuting at the Los Angeles International Auto Show (LAIAS) on November 17, 2021, embodies Mullen’s Southern California roots with an inspired design focused on two complementary Golden State themes – California landscape and California urban.

The FIVE is built on an EV Crossover skateboard platform that offers multiple powertrain configurations and trim levels in a svelte design that is Strikingly Different™ and exciting to experience in person.

Prior to the start of LAIAS, the Mullen FIVE was selected as a finalist by the LA Auto Show for Top EV SUV in the ZEVA “People’s Choice” Awards.

LAIAS provides Mullen an opportunity to display multiple variants of the FIVE model while also showcasing its powertrain, battery and charging technology. The company intends to bring the FIVE to market in 2024, and reservations are currently open here.

Mullen’s development portfolio also includes EV Fleet Vans, which it intends to bring to market in Q2 2022, and the pure electric, high performance Mullen DragonFLY.

Expansion of Manufacturing Capacity

On November 2, 2021, Mullen announced plans to expand its facility in Robinsonville, Mississippi.

Mullen’s Advanced Manufacturing and Engineering Facility (AMEC) currently occupies 124,000 square feet of manufacturing space. The total available land on the property is over 100 acres, and Mullen is moving ahead with plans to build out another 1.2 million square feet of manufacturing space to support class 1 and class 2 EV cargo vans and the Mullen FIVE EV Crossover.

On the expanded site, Mullen plans to build a body shop, a fully automated paint shop and a general assembly shop.

EV Market Outlook

The global EV market was reported to consist of 3,269,671 units in 2019, a figure that is expected to grow at a CAGR of 21.1% through 2030 to a total of 26,951,318 units worldwide. This market’s monetary value was estimated at $162.34 billion in 2019 and is expected to grow at a CAGR of 22.6%, resulting in an approximate value of $802.81 billion by 2027. The primary driver for this exponential growth is a worldwide increase in vehicle emissions regulations.

Management Team

David Michery is the CEO and Founder of Mullen and has been leading the company and its divisions since inception in 2014. With over 25 years of executive management, marketing, distressed assets, and business restructuring experience, Mr. Michery brings a wealth of relevant knowledge and expertise to the Mullen brand. He has notably created 12 trademarks so far to develop the company brand and vision.

Mr. Michery is working toward a sustainable future accessible to all by creating a suite of clean-energy electric vehicles at varied price points. With entirely U.S.-based manufacturing and operations, he is also determined to have Mullen Technologies play a role in shaping a self-sustaining local economy by creating more jobs in America.

Mr. Michery manages risks and company expectations as a pathway to success and has personally overseen several businesses that totaled over $1 billion in transactions. His key strength is the ability to be fiscally responsible and lead teams to complete projects on time and within budget. As a seasoned professional in this space, Mr. Michery has demonstrated skill in building businesses from the ground up and into successful entities that subsequently sold for hundreds of millions of dollars.

Mullen Automotive Inc. (MULN), closed Monday's trading session at $4, off by 11.6998%, on 2,519,148 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $2.3565/$661.50.

Recent News

Longeveron Inc. (NASDAQ: LGVN)

The QualityStocks Daily Newsletter would like to spotlight Longeveron Inc. (NASDAQ: LGVN) .

Longeveron (NASDAQ: LGVN) is a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions. The company today announced the launch of its contract development and manufacturing business at its 15,000-square-foot, state-of-the-art Good Manufacturing Practice ("GMP") facility. In addition, the company announced the initiation of work under its first manufacturing services contract with Secretome Therapeutics, a biotechnology company developing first-in-class therapeutics from neonatal mesenchymal stem cells ("nMSC"). "We are delighted to partner with Secretome Therapeutics to advance their portfolio of therapeutics in this, our first contract manufacturing agreement in a new, revenue generating business line," said Longeveron CEO Wa'el Hashad. "With cellular therapy manufacturing expertise and capabilities in high demand, and Longeveron's strength in both, we see a significant opportunity to employ currently unused capacity in our state-of-the-art GMP facility. We have assembled a team of experts and proprietary technologies that enable us to take a systematic approach to rapidly develop improved cell therapies. Longeveron's manufacturing expertise, capabilities and facility provide other pharmaceutical organizations the ability to advance their development programs without building their own manufacturing facility. We believe this contract manufacturing opportunity can expand our team's experience and has the potential to generate approximately $4-5 million in annual revenues once it is up and running fully."

To view the full press release, visit https://ibn.fm/dQkaV

Longeveron Inc. (NASDAQ: LGVN) is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. The Company’s research and therapies are aimed at improving the outcome of infants born with a life-threatening heart condition, as well as improving the healthspan for the aging population – the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging, with function and ability to perform activities of daily living.

Longeveron is involved in clinical trials in the following indications: Hypoplastic left heart syndrome (HLHS), Alzheimer’s disease, and Aging-related Frailty.

The Company’s philosophy revolves around the idea that regenerative medicine may hold the potential to improve certain rare medical conditions and contribute to healthy aging. While there has been a remarkable rise in life expectancy over the last century due to medical and public health advancements, this increase in longevity has not been paralleled by the number of years a person is expected to live in relatively good health, free of chronic disease and disabilities of aging.

Longeveron’s lead investigational product is Lomecel-B™, an allogeneic Medicinal Signaling Cell therapy product isolated from the bone marrow of young, healthy adult donors. As humans age, they experience a decrease in immune system function, a decline in blood vessel functioning, chronic inflammation, and other issues. Clinical data has suggested that Lomecel-B™ may address these conditions through multiple mechanisms of action (MOA) that simultaneously target key aging-related processes.

The Company is headquartered in Miami, Florida.

Lomecel-B™

Lomecel-B™ is being evaluated in multiple clinical trials for aging-related chronic diseases and other life-threatening conditions under U.S. FDA-approved Investigational New Drug applications. Lomecel-B™ has multiple potential mechanisms of action encompassing pro-vascular, pro-regenerative, anti-inflammatory, and tissue repair and healing effects with broad potential applications across a spectrum of disease areas.

The drug is made from special living cells called Medicinal Signaling Cells (MSCs) that are isolated from fresh bone marrow tissue that has been donated by adult donors aged 18 to 45. Once the MSCs have been isolated from the fresh bone marrow through a careful selection process, the cells are culture-expanded (allowed to replicate under controlled laboratory conditions) into the billions using specialized techniques and processes. After a specific number of expansion cycles, called “passages,” the cells are harvested, separated into specific doses (e.g., 50 million cells), and cryopreserved until future use.

These cells have been shown to have characteristics that allow them to be transplanted from a donor to host without triggering a harmful immune response in the recipient, and they can be administered on an outpatient basis in as little as 40 minutes after thawing. Because of these characteristics, Lomecel-B™ is considered an “off-the-shelf” product.

In some trials, such as for Alzheimer’s disease and Aging-related Frailty, Lomecel-B™ is administered via peripheral intravenous infusion, while, in the Company’s HLHS trial, Lomecel-B™ is administered via direct injection into the heart tissue.

Market Opportunity

Longeveron estimates the potential market size for Lomecel-B™ in the treatment of HLHS to be up to $1 billion annually, globally.

U.S. patients suffering from Aging-related Frailty are estimated using U.S. Census Bureau statistics to be approximately 8.1 million. That population potentially represents a market for Lomecel-B™ of between $4 billion and $8 billion globally per year, according to Company estimates.

Additionally, the Alzheimer’s Association puts the number of Americans with that disease at 5.1 million, highlighting another potentially addressable market for Lomecel-B™, that’s worth $5 billion to $10 billion annually.

Management Team

Wa’el Hashad is CEO of Longeveron. He has more than 35 years of experience in the pharmaceutical and biotech industries. He has launched several successful brands in the U.S. and worldwide markets. Prior to joining Longeveron, he was president and CEO of Avanir Pharmaceuticals. Before Avanir, he was the chief commercial officer of Seres Therapeutics. He also has held senior leadership positions at Amgen, Boehringer Ingelheim, and Eli Lilly and Company. He holds a bachelor’s degree in pharmacy from Cairo University and an MBA from the University of Akron.

Joshua M. Hare, M.D., FACC, FAHA, is Co-Founder, Chief Science Officer and Chairman of Longeveron. He is a double board-certified cardiologist and is the founding director of the Interdisciplinary Stem Cell Institute at the University of Miami’s Miller School of Medicine. He is a recipient of the Paul Beeson Physician Faculty Scholar in Aging Research Award and is an elected member of the American Association of Physicians and The American Society for Clinical Investigation. He is also an elected Fellow of the American Heart Association. He received a bachelor’s degree from the University of Pennsylvania and his M.D. from The Johns Hopkins University School of Medicine.

Lisa Locklear is CFO at Longeveron. She previously served as the senior vice president and CFO for Avanir Pharmaceuticals. Prior to Avanir, she held senior financial roles at GSN Games, CoreLogic, Ingram Micro, the Walt Disney Company, and Price Waterhouse, with assignments in Paris and London. She holds a bachelor’s degree in plant science from the University of California, Davis, and an MBA from the University of California, Irvine. She is a licensed CPA (inactive) and is a member of the American Institute of Certified Public Accountants, the California Society of CPAs, and Financial Executives International.

Dr. Nataliya Agafonova, M.D., is the Chief Medical Officer at Longeveron. She previously served as clinical development lead, senior medical director, and product development chair at Otsuka Pharmaceuticals. Before that, she was the clinical development lead and senior medical director at Bristol-Myers Squibb. She previously held senior leadership positions at Ardea Bioscience, Biogen, Amgen, and Genzyme Corporation. She earned an M.D. from the Ukrainian National Medical University and completed her internal medicine residency at Kharkov State University Hospital in Ukraine.

Certain statements in this corporate profile that are not historical facts are forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, which reflect management’s current expectations, assumptions, and estimates of future operations, performance and economic conditions, and involve risks and uncertainties that could cause actual results to differ materially from those anticipated by the statements made herein. Forward-looking statements are generally identifiable by the use of forward-looking terminology such as “believe,” “expects,” “may,” “looks to,” “will,” “should,” “plan,” “intend,” “on condition,” “target,” “see,” “potential,” “estimates,” “preliminary,” or “anticipates” or the negative thereof or comparable terminology, or by discussion of strategy or goals or other future events, circumstances, or effects. Factors that could cause actual results to differ materially from those expressed or implied in any forward-looking statements in this release include, but are not limited to, statements regarding the offer and sale of securities, the terms of the offering, about the ability of Longeveron’s clinical trials to demonstrate safety and efficacy of the Company’s product candidates, and other positive results; the timing and focus of the Company’s ongoing and future preclinical studies and clinical trials and the reporting of data from those studies and trials; the size of the market opportunity for the Company’s product candidates, including its estimates of the number of patients who suffer from the diseases being targeted; the success of competing therapies that are or may become available; the beneficial characteristics, safety, efficacy and therapeutic effects of the Company’s product candidates; the Company’s ability to obtain and maintain regulatory approval of its product candidates in the U.S., Japan and other jurisdictions; the Company’s plans relating to the further development of its product candidates, including additional disease states or indications it may pursue; the Company’s plans and ability to obtain or protect intellectual property rights, including extensions of existing patent terms where available and its ability to avoid infringing the intellectual property rights of others; the need to hire additional personnel and the Company’s ability to attract and retain such personnel; the Company’s estimates regarding expenses, future revenue, capital requirements and needs for additional financing; the Company’s need to raise additional capital, and the difficulties it may face in obtaining access to capital, and the dilutive impact it may have on its investors; the Company’s financial performance and ability to continue as a going concern, and the period over which it estimates its existing cash and cash equivalents will be sufficient to fund its future operating expenses and capital expenditure requirements. Additionally, Longeveron makes no assurance that any public offering of its securities as described herein will occur on the timelines, in the manner or on the terms anticipated due to numerous factors. Further information relating to factors that may impact the Company’s results and forward-looking statements are disclosed in the Company’s filings with the Securities and Exchange Commission, including Longeveron’s Annual Report on Form 10-K for the year ended December 31, 2022, filed with the Securities and Exchange Commission on March 14, 2023 and its Quarterly Report on Form 10-Q for the second quarter of 2023 filed with the SEC on August 11, 2023. The forward-looking statements contained in this corporate profile are made as of the date of this corporate profile, and the Company disclaims any intention or obligation, other than imposed by law, to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Investor Contact
Mike Moyer
LifeSci Advisors
Tel: 617-308-4306
Email: mmoyer@lifesciadvisors.com

Date prepared: August 31, 2023

Longeveron Inc. (NASDAQ: LGVN), closed Monday's trading session at $1.04, off by 5.4545%, on 2,124,842 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $1.02/$40.00.

Recent News

CNS Pharmaceuticals Inc. (NASDAQ: CNSP)

The QualityStocks Daily Newsletter would like to spotlight CNS Pharmaceuticals Inc. (NASDAQ: CNSP).

Patients with brain cancer often undergo surgery to treat the disease because this is the recommended treatment for this particular cancer. This doesn't mean that surgery is always an option, as treatments for patients are often prescribed by their primary care providers. A trial conducted at the Virginia-Maryland College of Veterinary Medicine (Virginia Tech) looked into whether noninvasive treatments would do away with surgery in the management of brain cancer. For their study, the researchers used dogs to test out the effectiveness of focused ultrasound therapy, in particular histotripsy, in getting rid of brain tumors. The researchers hope that in the long-term, the treatment will allow therapy to be administered and standard CT or MRI imaging to confirm during follow-up that the tumor isn't viable anymore, without having to surgically remove it. The researchers are currently planning follow up research on their study. As that follow-up research is conducted, enterprises such as CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also conducting extensive work to bring to market superior therapeutics aimed at combating brain cancers more effectively in comparison to the current approaches.

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, today announced a 1-for-50 reverse split of its common stock, effective at 4:01 p.m. ET on June 4, 2024. According to the update, beginning on June 5, 2024, the company's common stock will continue to trade on the Nasdaq Capital Market on a split adjusted basis under the trading symbol CNSP, but will trade under the following new CUSIP number: 18978H300. The move is primarily intended to increase CNSP's share trading price and bring the company into compliance with the Nasdaq's listing requirement regarding minimum share price.

To view the full press release, visit https://ibn.fm/pGXlQ

CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is a clinical stage biotechnology company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system.

The company was founded in 2017 and is headquartered in Houston, Texas.

Organ Targeted Therapeutics

The company’s lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (“GBM”), an aggressive and incurable form of brain cancer. Berubicin also has potential to treat other central nervous system malignancies. Based on limited clinical data, Berubicin appears to be the first anthracycline to cross the blood brain barrier in the adult brain, and it was the subject of a successful Phase 1 study which found the MDT and produced efficacy data as well.

CNS holds a worldwide exclusive license to the Berubicin chemical compound. The company has acquired all requisite data and know-how from Reata Pharmaceuticals Inc. related to a completed Phase I clinical trial of Berubicin in malignant brain tumors. In this trial, 44% of patients experienced a statistically significant improvement in clinical benefit. In 2017, CNS entered into a collaboration and asset purchase agreement with Reata.

CNS intends to explore the potential of Berubicin to treat other diseases, including pancreatic and ovarian cancers and lymphoma. The company is also examining plans to develop combination therapies that include Berubicin.

CNS estimates that more than $25 million in private capital and grants were invested in Berubicin prior to the company’s $9.8 million IPO in November 2019.

CNS intends to submit an IND for Berubicin during the fourth quarter of 2020 and expects to commence a Phase II clinical trial of Berubicin for the treatment of GBM in the U.S. in Q1 2021. A sub-licensee partner was awarded a $6 million EU/Polish National Center for Research and Development grant to undertake a Phase II trial of Berubicin in adults and a first-ever Phase I trial in pediatric GBM patients in Poland in 2021.

The company’s second drug candidate, WP1244, is a novel DNA binding agent licensed from the MD Anderson Cancer Center. In preclinical studies, WP1244 proved to be 500-times more potent than the chemotherapeutic agent, daunorubicin, in inhibiting tumor cell proliferation. The company has entered into a sponsored research agreement with the MD Anderson Cancer Center to further the development of WP1244.

CNS Pharmaceuticals recently engaged U.S.-based Pharmaceutics International Inc. and Italian BSP Pharmaceuticals SpA for the production of the Berubicin drug product. The company has implemented a dual-track manufacturing strategy to mitigate COVID-19-related risks, diversify its supply chain and provide for localized availability of Berubicin. CNS has already completed synthesis of Berubicin’s active pharmaceutical ingredient (API) and has shipped the API to both manufacturers in order to prepare an injectable form of Berubicin for clinical use.

Global Brain Tumor Therapeutics Market

The high recurrence rate of malignant brain tumors is due to reappearance of focal masses, indicating that a sub-population of tumor cells in these cancers may be insensitive to current therapies and may be responsible for reinitiating tumor growth. This necessitates the development of newer drugs in the market that demonstrate greater efficacy in treating such aggressive cancers.

A global increase in neurological disorders has placed increased attention on cancers of the brain over the past decade. Neurological disorders are becoming one of the most prevalent types of disorders, due to longer life expectancy, greater exposure to infection and an increasingly sedentary lifestyle. Because few treatments for primary and metastatic cancers of the brain exist, costs are high and have acted as a restraint for the brain tumor therapeutics market.

Despite progress in surgery, radiotherapy and chemotherapeutic strategies, effective treatments for brain cancer are limited by a lack of specific therapies for the brain and the difficulty in transporting therapeutic compounds across the blood brain barrier. Therefore, there is a significant need for novel and effective therapeutic drugs and strategies that prolong survival and improve quality of life for brain tumor patients.

Several companies are making significant investments into R&D, which is expected to bring more treatment options to the market in the near future. Industry reports consistently project continued growth in the market.

One report estimates that the global brain tumor therapeutics market will reach a valuation of $2.74 billion in 2023, with the market expected to register a CAGR of 11% during the forecast period from 2018 to 2023. Another report projects that the global brain tumor therapeutics market will reach $3.4 billion by 2025, up from $2.25 billion in 2019 (http://nnw.fm/eDUjp).

Management Team

John M. Climaco is the CEO of CNS Pharmaceuticals. For 15 years, Climaco has served in leadership roles for a variety of health care companies. Recently, Climaco served as the Executive Vice President of Perma-Fix Medical S.A, where he managed the development of a novel method to produce Technitium-99. Climaco also served as President and CEO of Axial Biotech Inc., a DNA diagnostics company. In the process of taking Axial from inception to product development to commercialization, Climaco forged strategic partnerships with Medtronic, Johnson & Johnson and Smith & Nephew.

Christopher Downs, CPA, is the company’s Chief Financial Officer. Downs previously served as Interim Chief Financial Officer and Executive Vice President of InfuSystem Holdings Inc. (NYSE: INFU), a supplier of infusion services to oncologists in the United States. Downs holds a Bachelor of Science from the United States Military Academy at West Point, an MBA from Columbia Business School and a Master of Science in Accounting from the University of Houston-Clear Lake.

Dr. Donald Picker is the Chief Scientific Officer of CNS. Picker has over 35 years of drug development experience. Prior to joining CNS, Picker worked at Johnson Matthey, where he was responsible for the development of Carboplatin, one of the world’s leading cancer drugs, which was acquired by Bristol-Myers Squibb with annual sales of over $500 million. In addition, he oversaw the development of Satraplatin and Picoplatin, third-generation platinum drugs currently in late-stage clinical development.

Sandra L. Silberman, M.D., Ph.D., is the Chief Medical Officer of CNS Pharmaceuticals. Silberman is a hematologist/oncologist who earned her B.A., Sc.M. and Ph.D. from the Johns Hopkins University School of Arts and Sciences, School of Public Health and School of Medicine, respectively, and her M.D. from Cornell University Medical College. She then completed both a clinical fellowship in hematology/oncology and a research fellowship in tumor immunology at the Brigham & Women’s Hospital and the Dana Farber Cancer Institute in Boston, Massachusetts. Silberman has played key roles in the development of many drugs, including Gleevec(TM), for which she led the global clinical development at Novartis. Silberman advanced several original, proprietary compounds into Phases I through III during her work with leading biopharmaceutical companies, including Bristol-Myers Squibb, AstraZeneca, Imclone and Roche.

CNS Pharmaceuticals Inc. (NASDAQ: CNSP), closed Monday's trading session at $0.13, off by 39.8705%, on 9,434,095 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.128/$2.91.

Recent News

HealthLynked Corp. (OTCQB: HLYK)

The QualityStocks Daily Newsletter would like to spotlightFathom HealthLynked Corp. (OTCQB: HLYK) .

HealthLynked is at the forefront of revolutionizing global healthcare related solutions for patients, doctors, and related healthcare organizations

Some of the company's solutions, including the HealthLynked Network, Augmented Real-Time Interface, and the new AI chat feature, incorporate artificial intelligence capabilities to foster better patient outcomes for all

The new AI chat feature is designed to assist patients in locating healthcare providers across the country using markers such as name, specialty, or location and significantly enhance the effectiveness of the HealthLynked Concierge Team in reducing wait times and offering 24/7 service to users

HealthLynked continues to lead in the development of advanced AI tools to meet the evolving needs of the healthcare sector

HealthLynked (OTCQB: HLYK) develops and deploys innovative healthcare solutions, serving patients, doctors, and support services, by leveraging advanced technology to provide more efficient, accessible, and personalized healthcare information whenever and wherever it is needed. One of these solutions is the HealthLynked Network, a sophisticated cloud-based platform and app designed to facilitate the seamless exchange of medical information between patients and healthcare providers.

HealthLynked Corp. (OTCQB: HLYK) is at the forefront of a transformative movement in healthcare, utilizing its extensive collection of health data to improve care for all. With a commitment to leveraging its advanced technology platforms, HealthLynked employs a sophisticated, cloud-based network that serves as a comprehensive repository for personal health data. This system not only simplifies the management and archiving of medical records but also enables the application of AI to deliver personalized healthcare insights. Through deep analysis of this data, HealthLynked’s AI capabilities help identify the root causes of diseases, tailor healthcare solutions to individual needs, and accelerate medical discoveries.

HealthLynked Corp. App

In addition to these capabilities, HealthLynked provides a user-friendly platform for booking healthcare appointments, similar to how OpenTable operates for restaurant reservations. This feature allows patients to conveniently book appointments with healthcare providers across the country, including options for telemedicine consultations, enhancing accessibility and efficiency in healthcare service delivery.

Strategically headquartered in Naples, Florida, HealthLynked operates through three primary divisions: Health Services, Digital Healthcare, and Medical Distribution. Each division supports the company’s mission to revolutionize patient care and health management. Positioned as a potential leader in healthcare AI, HealthLynked is dedicated to shaping the future of the industry over the next 20 years, driving significant advancements in healthcare accessibility and effectiveness through innovation and technology.

HealthLynked Corp. Reach

Strategic Initiatives and Operational Highlights

The company’s commitment to enhancing global health is evident in its dual goals: transforming healthcare through advanced technology and creating a patient-centric network that accelerates medical discoveries and the development of disease cures.

HealthLynked’s intellectual property portfolio is robust and strategically developed to enhance healthcare delivery and management. In March 2023, HealthLynked was granted a patent for a groundbreaking healthcare-specific wireless access point, known as the “Patient Access Hub.” This technology significantly improves the efficiency of healthcare practices by enabling real-time monitoring of patient flow within facilities. It intelligently determines patients waiting in exam rooms and calculates wait times, alongside other critical practice metrics. This system not only enhances patient experience by reducing unnecessary wait times but also optimizes resource allocation within healthcare settings.

Additionally, in October 2023, HealthLynked filed a patent application for its advanced AI program, ARI (Augmented Real-time Interface). ARI acts as a virtual doctor for patients, capable of performing medical intake, booking appointments, and providing personalized medical recommendations based on a patient’s medical history. By integrating these tasks, ARI streamlines the healthcare process, reducing the administrative burden on healthcare providers and ensuring that patients receive timely and tailored healthcare advice. This AI-driven interface enhances the accessibility and personalization of healthcare, embodying HealthLynked’s commitment to leveraging technology for better health outcomes. The company recently launched HealthLynked 3.2.0, an advanced version of its application, incorporating telemedicine, AI-driven personal healthcare guidance, and remote patient monitoring – setting a new standard in healthcare technology.

Market Position and Future Outlook

According to Facts and Figures Research, a research and consulting firm, the global market for patient-centric healthcare applications is projected to reach $41.6 billion by 2030, growing at a CAGR of 18.77% from 2022. HealthLynked’s offerings align perfectly with this expansive market opportunity, especially with increasing demands for digital health solutions and data management in healthcare.

HealthLynked’s strategic direction, spearheaded by its seasoned management team, is designed to leverage these market dynamics, enhancing patient engagement and healthcare efficiency on a global scale.

Management Team

Michael T. Dent, M.D., Founder, CEO, and Chairman, brings extensive experience from his foundational role at NeoGenomics and leadership in various healthcare and technology sector companies.

David Rosal, CFO, with previous senior roles at Teradata and McDonald’s Corporation, brings a wealth of expertise in financial and business integration strategies essential for growth and operational efficiency.

Chris Hall, CTO, with a strong background in global technology development from his time at Siemens and several patents to his name, is instrumental in driving the innovation and technological advancement at HealthLynked.

Bill Crupi, Operations Manager, has a proven track record in streamlining operations and enhancing productivity across multiple sectors within the healthcare industry. His expertise is crucial in maintaining the operational excellence that HealthLynked is known for.

Michael Paisan, Director of Investor Relations, leverages his extensive experience in finance and communications to enhance HealthLynked’s relationships with investors and stakeholders, ensuring transparent and effective communication of the company’s value and growth strategy.

Gagan Babber, Manager of Software Development, oversees the HealthLynked development teams based in the U.S. and India. With a robust background in engineering and software development, he plays a critical role in guiding the technological direction of HealthLynked’s products. His expertise in developing scalable, innovative software solutions is essential for driving the company’s technical initiatives forward and ensuring that HealthLynked stays at the forefront of digital healthcare technology.

HealthLynked Corp. (OTCQB: HLYK), closed Monday's trading session at $0.0497, off by 5.3333%, on 527,758 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.033/$0.0999.

Recent News

ECGI Holdings Inc. (OTC: ECGI)

The QualityStocks Daily Newsletter would like to spotlight ECGI Holdings Inc. (OTC: ECGI).

ECGI Holdings is implementing an ongoing strategy to streamline its financials and improve its overall financial health, including the successful reduction of nearly $1.5 million in liabilities, a move seen as integral to its long-term strategy of continually improving its financial posture and overall economic vitality

ECGI is also focused on exploring new pathways to monetize its underutilized assets, expanding its footprint within the luxury space with a specific focus on carving a niche in luxury branding and creating a luxurious short-term rental destination

Looking ahead, ECGI will continue to focus on identifying and capitalizing on growth opportunities that align with its business objectives

ECGI Holdings (OTC: ECGI), a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion, is implementing a broad strategy to streamline its financials and improve its overall financial health. This is part of the company's financial optimization initiative aimed at strengthening its financial structure, cleaning up its balance sheet, reducing its liabilities, and boosting shareholder value.

ECGI Holdings Inc. (OTC: ECGI) is a diversified holding company with a distinctive portfolio encompassing viticulture and luxury fashion. The company owns and manages a five-acre vineyard in Lake County, California, specializing in cultivating the Petite Sirah varietal, known for its bold and rich character, aligning with the growing demand for unique and high-quality wine experiences.

In the fashion sector, ECGI has strategically invested in Pacific Saddlery, a premier manufacturer and retailer of luxury equestrian tack, apparel and accessories. This unique blend of wine and fashion investments reflects ECGI Holdings’ commitment to delivering sophistication and innovation across diverse markets, positioning the company as a distinctive player in the intersection of technology, viticulture and luxury lifestyle.

Moving forward, ECGI Holdings is focused on identifying and capitalizing on growth opportunities that align with the company’s business objectives and continuing to improve its financial structure. In 2024, ECGI Holdings was approved by Evolve — a distinguished name in vacation rental management. This partnership will transform the company’s 40-acre Lake County property into a luxurious short-term rental destination aptly named Vintner’s Caldera Ranch.

ECGI Holdings is excited about the possibilities that Vintner’s Caldera Ranch creates for shareholders and looks forward to further developments poised to unlock the value of other underutilized assets. The company believes that it is laying a solid foundation for sustained success and profitability in the years to come.

ECGI Holdings is headquartered in Irvine, California.

Operational Philosophy

ECGI Holdings has embarked on an ambitious new vision and strategic direction to build and nurture luxury brands that resonate with its core values and market aspirations. Its joint venture with Pacific Saddlery epitomizes ECGI Holdings’ strategic shift toward luxury branding, leveraging Pacific Saddlery’s tangible and established market presence in equestrian products.

This transition will also allow ECGI Holdings to explore new pathways to monetize its underutilized assets, including the company’s vineyard. A key highlight of the company’s future outlook is the debut of Pacific Saddlery’s new mobile retail boutique at specific equestrian events in 2024. This innovative venture represents a significant step in ECGI Holdings’ strategy to enhance brand visibility and engage directly with the company’s target market.

In addition, the Vintner’s Caldera Ranch development marks a significant step in advancing the company’s strategy to revitalize and leverage underutilized assets. Vintner’s Caldera Ranch is set against the backdrop of Lake County’s breathtaking scenery, offering an exclusive getaway experience that blends natural beauty with luxury. Choosing Evolve is a strategic move to ensure that Vintner’s Caldera Ranch not only meets but exceeds the high standards of service that luxury guests expect.

Evolve’s expertise in maximizing rental potential and delivering exceptional guest experiences is crucial to the company’s vision of making Vintner’s Caldera Ranch a preferred choice for discerning travelers. With this venture, ECGI Holdings is not only expanding its footprint within the luxury rental marketplace, but also contributing to the local economy and enhancing the appeal of Lake County as a tourist destination.

The company’s focus remains steadfast on strategic growth, operational excellence and customer satisfaction.

Market Outlook

A report from Grand View Research, a global market research and consulting company, estimated the value of the worldwide luxury brands market at $366.23 billion in 2023 and projects the market to grow to a value of $580.43 billion by 2030, achieving a CAGR of 6.8% over the forecast period.

Rising disposable income and wealth in various regions of the world, particularly in emerging markets such as China and India, have propelled the growth of the market, according to the report.

Younger consumers, such as millennials and Generation Z, are increasingly entering the luxury market, driving demand for more contemporary and experiential luxury offerings. The rise of social media and influencer marketing has greatly impacted the visibility and desirability of luxury products, the report states.

Management Team

Jamie Steigerwald is CEO of ECGI Holdings, Inc. He is a successful entrepreneur with over 30 years of experience. Most recently, he was COO of Sugarmade Inc. (OTC: SGMD), a California cannabis real estate, cultivation, manufacturing and services company. He is the owner of SwiftLead, an Orange County web marketing, design and development company. He previously was COO for First USA Home Loans, a retail mortgage lender, and co-founder and President of SwiftLead Software, a mortgage lead tracking system.

Nick Collins is CEO at Pacific Saddlery. He brings over 25 years of expertise in equestrian luxury goods. He previously founded Rolling Meadows and created the Allon Equestrian and Renard et Cheval apparel brands. He was instrumental in creating and launching Kaval.com, an online equestrian apparel and accessories site.

ECGI Holdings Inc. (OTC: ECGI), closed Monday's trading session at $0.0021, off by 4.5455%, on 543,032 volume. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0016/$0.0198.

Recent News

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX)

The QualityStocks Daily Newsletter would like to spotlight McEwen Mining Inc. (NYSE: MUX) (TSX: MUX).

McEwen Mining Inc. (NYSE: MUX) (TSX: MUX) is an asset rich diversified gold and silver producer in the Americas with a large exposure to copper through its subsidiary, McEwen Copper, owner of the Los Azules copper deposit in Argentina, believed to be the 8th largest undeveloped copper resource in the world.

Led by a management team with a track record of success, MUX owns and operates mines in some of the most prolific gold producing regions of the Americas. The company proactively took cost-saving measures months ago to lower expenses and increase production across its portfolio of gold assets, driving some production costs below industry averages. Gold and copper prices, already in an upswing, are forecast to enter an explosive uptrend over the next couple years. Drawing from its experience, McEwen Mining planned, prepared and laid the groundwork to capitalize on this emerging opportunity.

The company currently holds a Zacks Rank #1 (Strong Buy), placing it in the top 5% of over 4,000 stocks ranked by Zacks, based on trends in earnings estimate revisions and EPS surprises. Seldom is management so aligned with investors’ interests and committed to the company’s success. With a combined investment of over $220 million, CEO Rob McEwen holds a 17% ownership stake in McEwen Mining and a 13% ownership in McEwen Copper. Acclaimed in the mining industry, McEwen founded Goldcorp, where he increased the company’s market capitalization 160 times – from $50 million to over $8 billion. That same vision and tenacity led MUX in creating McEwen Copper.

For McEwen Mining shareholders, beyond the company’s exposure to gold upsurges, its 47.7% stake in McEwen Copper is expected to be a blockbuster, turbocharging MUX by creating the world’s next prolific copper unicorn.

McEwen Copper

With continuous industrial need, new critical demand for copper is rapidly emerging, increasingly driven by the green energy transition. The price of copper rose from a low of about $2 per pound in 2020 to over $4.60 per pound in May 2024, and strong demand is expected to intensify. A study by S&P Global, titled The Future of Copper: Will the Looming Supply Gap Short-circuit the Energy Transition?, projects global copper demand to nearly double over the next decade, from 25 million metric tons today to about 50 million metric tons by 2035. Based on current trends, S&P Global forecasts annual supply shortfalls to reach nearly 10 million metric tons in 2035.

McEwen Mining owns a 47.7% equity stake in McEwen Copper, the holder of a 100% interest in the Los Azules copper project in San Juan, Argentina, which is ranked the 8th largest undeveloped copper deposit in the world. Current copper resources at Los Azules are estimated at 10.9 billion pounds at a grade of 0.40% Cu (Indicated category) and an additional 26.7 billion pounds at a grade of 0.31% Cu (Inferred category). McEwen Copper also owns a copper exploration project in Nevada, USA, called Elder Creek.

In a 2023 Preliminary Economic Assessment (PEA), Los Azules was estimated to have a 27-year life, producing an average of 322 million lbs. of copper cathode annually, at a cash cost of $1.07 per lb. of copper, in the lowest quartile of the copper cost curve. The project could ultimately become an even larger mine with a longer life, since the extent of mineralization has not been fully assessed on the property.

The project’s 2023 PEA presents a distinctly different development strategy from a prior PEA published in 2017. By proposing a heap leach project using solvent extraction-electrowinning instead of the previously detailed mine with a conventional mill and flotation concentrator, McEwen Copper aims to decrease its environmental footprint and reduce permitting risk, albeit with a lower overall copper recovery, slightly higher unit costs and a delay in immediate cashflow due to extended leach cycles.

After securing a $25 million investment from mining giant Rio Tinto’s technology arm, Nuton LLC, McEwen Copper closed its non-brokered, private placement offering of $82 million in August 2022. Shortly after, in February 2023, Nuton agreed to invest an additional $30 million into McEwen Copper, and in October 2023, Nuton once again expanded its stake, investing an additional $10 million to bring its ownership position in McEwen Copper to 14.5%.

“We are extremely pleased to have Nuton’s strong continued participation in McEwen Copper,” Rob McEwen stated in a news release. “Together we are exploring new technologies that save energy, water, time and capital in the pursuit of delivering green copper to Argentina and the world, a product that will contribute to the electrification of transportation and the protection of our atmosphere.”

Also in February 2023, FCA Argentina S.A., a subsidiary of Stellantis N.V., one of the world’s leading automakers, invested ARS $30 billion in McEwen Copper. In October 2023, Stellantis invested an additional ARS $42 billion, bringing its current stake in McEwen Copper to 19.4%.

“We are delighted to have Stellantis as a partner in the future development of our Los Azules copper project,” Rob McEwen said of the investment. “Together, we share a vision to build a mine for the future based on regenerative principles that can achieve net-zero carbon emissions by 2038.”

Following the capital raise, McEwen Copper is well-funded to advance its Los Azules Project, with a Feasibility Study planned for Q1 2025. MUX strategically reduced its interest to increase its treasury, in order to reduce debt and fund the further development of its gold and silver assets.

Gold & Silver Projects

The Fox Complex

McEwen Mining owns a 100% stake in the Fox Complex in the heart of a prolific gold district in Timmins, Canada.

“When MUX bought the Fox Complex, in late 2017, it was a distressed asset with a history of high operating cost/oz. While it has taken longer than I expected, the cost to produce an ounce of gold is significantly lower,” CEO Rob McEwen stated in a news release.

McEwen Mining issued 2024 guidance for its cash cost/oz at the Fox Complex of $1,225-1,325 on annual production of 40,000-42,000 GEOs. Fox Complex produced 44,450 GEOs in 2023, which was within the company’s guidance range.

Located in one of the most prolific gold production areas in the world, along the Destor-Porcupine Fault Zone within the Abitibi Greenstone Belt, the Fox Complex includes the Black Fox mine and Froome mine which together have yielded over 1,000,000 ounces of gold to date. Also, the complex includes the Grey Fox and Stock deposits that have over 1,800,000 ounces in gold resources. The 2.7-billion-year-old Abitibi Greenstone Belt, formed by ancient volcanic activity, has proved to be one of the world’s richest and most abundant gold regions, with a total gold content currently estimated at over 300 million ounces.

In 2024, MUX commenced development of underground ramp access to the Stock orebodies at the Fox Complex. This development will become the primary source of feed following the completion of mining the Froome deposit in 2026. As part of the future mining sequence initiative, the company has already reported a 31% year-over-year increase of gold resources at Stock West and Stock Main (historical Stock Mine), with confirmation of good grading structures plunging to depth. It has also identified Stock East as a potential new near-term source of future revenue.

The Gold Bar Mine

McEwen Mining owns a 100% stake in the Gold Bar mine, located in an area well known for gold production, the southern Roberts Mountains of the Battle Mountain-Eureka-Cortez gold trend in Eureka County, Central Nevada. The Gold Bar mine is on the same geological structure, 25 miles south of Nevada Gold Mines, a Barrick-Newmont joint venture, part of the Cortez-Goldrush complex. This complex contains estimated reserves and resources of over 50 million gold ounces, with an annual production of 1,000,000 gold ounces.

Gold Bar had been mined between 1991 and 1994, producing 134,000 gold ounces. A new facility was built by MUX in 2019. Gold Bar accounted for 42,700 GEOs in 2023, within the company’s guidance for the year. For 2024, McEwen Mining issued guidance of 40,000-43,000 at a cash cost of $1,450-1,550. The first half of the year is expected to deliver higher production relative to the second half, due to a scheduled waste stripping phase in the Pick pit, in preparation for the 2025 mining program.

Notably, in April 2024, McEwen Mining announced its entry into a definitive agreement and plan of merger with Timberline Resources Corporation (TSX.V: TBR) (OTCQB: TLRS) in a transaction valued at roughly $18.8 million. The merger with Timberline is expected to augment McEwen’s existing portfolio of development and exploration projects in Nevada, leveraging synergies between Timberline’s projects and the Company’s Gold Bar mine.

El Gallo/Fenix

Project Fenix is the proposed redevelopment plan for McEwen Mining’s El Gallo Complex in Mexico. There is a long history of mining in this region. MUX began operating it as an open pit, heap leach mine in 2013, which produced 281,000 gold equivalent ounces at average cash cost of $655 per ounce. Due to the transition to deeper sulfide mineralization that is not amenable to heap leaching, mining activities ceased in the second quarter of 2018 and residual heap leaching followed until mid-2022. The redevelopment plan envisions constructing a mill at the existing mine site that will initially reprocess the existing heap leach material, then transition to open pit mining and processing of the sulphide mineralization. The company recently acquired a complete process plant on very advantageous terms that has considerably reduced the projected capital requirements for the project.

CEO Rob McEwen stated in a news release, “This acquisition has made Fenix more attractive to build and could provide a new long life mine for McEwen Mining.”

The initial development approach is to build a mill to reprocess the material on the heap leach pad and produce approximately 17,000 oz of gold annually for eight years. Construction of the Fenix project is expected to begin in the second half of 2024.

San José Mine

McEwen Mining is a 49% owner and non-operator of the San José gold and silver mine, located in Santa Cruz province, Argentina, encircling Newmont’s prolific Cerro Negro (approx. 300,000 gold ounces produced in 2023). This high-grade underground mine has been operating since 2007 and currently has an expected life of six years with a reserve grade of 296 gpt silver and 5.4 gpt gold.

Exploration is continuing to extend high-grade veins and discover new veins at the complex. San José’s drilling programs to define additional resources and reserves have a long history of success due to a high vein density, aided by good geophysical response from hidden veins.

Production guidance for 2024 for MUX’s 49% interest is 50,000-60,000 GEOs. As a minority shareholder in the mine, MUX equity accounts for its investment in San José, and receives 49% of the dividends from the mine’s free cash flow.

Market Outlook

Mining stocks suffered significant losses in the wake of the COVID-19 pandemic. However, this has turned, and many analysts now forecast a gold bull market in 2024 and beyond.

“The operating challenges we faced in recent years have severely damaged our credibility with our shareholders and the market. As a result, few investors have taken a close look recently at our assets,” Rob McEwen said in a news release. “If they did, I believe some would see the potential value that I see today… I believe there is considerable potential value in MUX, and that is a big reason why I have a personal financial commitment of $220 million in MUX and McEwen Copper.”

Management Team

Robert R. McEwen is Chairman, CEO and Chief Owner of McEwen Mining. He has been associated with the gold industry all his career, with his first 18 years in the investment industry and, since 1990, as CEO of several gold mining companies. He founded Goldcorp and took that company from a $50 million market capitalization to more than $8 billion. He owns 17% of McEwen Mining and is in complete alignment with investors – his investment in MUX and McEwen Copper is $220 million and he takes an annual salary of only $1. He was awarded the Order of Canada and the Queen Elizabeth’s Diamond Jubilee Award, was inducted into the Mining Hall of Fame, was named an Ernst and Young Entrepreneur of the Year and has Honorary Doctor of Law degrees from York University and Western University.

William Shaver is interim COO and a Director of McEwen Mining. He has decades of management and executive experience in mine design, construction and operations. He was a founder of Dynatec Corporation, which became one of the leading contracting and mine operating groups in North America. In 2013, he was recognized as Ernst and Young Entrepreneur of the Year. Most recently, he served as COO of INV Metals. He is a Professional Engineer with a B.Sc. in Mining Engineering from Queens University.

Perry Ing is interim CFO at McEwen Mining. He has 25 years of experience in the Canadian mining industry. Over the past 15 years, he has held positions as CFO of Mountain Province Diamonds, Kirkland Lake Gold and McEwen Mining. Prior to that, he worked at Barrick Gold and Goldcorp and started his career in the mining practice at PwC. He has a Bachelor of Commerce from the University of Toronto and is a Chartered Professional Accountant in Canada and Certified Professional Accountant in the U.S.

Adrian Blanco S. is the company’s Director of Operations for America and Mexico. He has extensive international experience in several industrial sectors and has held executive positions in Mexico, the United States, Peru and Argentina. He joined the McEwen Mining team in 2015 and has led a successful business transformation toward operational discipline, best business practices and financial profitability at subsidiaries Compañia Minera Pangea and McEwen Mining Nevada. He graduated from an Executive Management Program at IPADE and Harvard Business School.

Michael Meding is Vice President and General Manager of McEwen Copper. He has over 20 years of international experience, primarily with major mining companies such as Barrick Gold and Trafigura, including extensive experience with project development and operations in Argentina. While at Barrick Gold’s Veladero mine in Argentina, Mr. Meding played a key role in the turnaround, extension of the mine life and subsequent strategic partnering with Shandong Gold. He holds an MBA from Indiana University in Pennsylvania and an MBA from the Leipzig Graduate School of Management in Germany.

McEwen Mining Inc. (NYSE: MUX), closed Monday's trading session at $11.93, up 0.1679261%, on 568,056 volume. The average volume for the last 3 months is 950,587 and the stock's 52-week low/high is $5.92/$12.50.

Recent News

GEMXX Corp. (OTC: GEMZ)

The QualityStocks Daily Newsletter would like to spotlight GEMXX Corp. (OTC: GEMZ) .

GEMXX Corp. (OTC: GEMZ) is a mine-to-market enterprise specializing in gold, gemstone, and jewelry production. With ownership of mining resources, production facilities, and operational assets, the company maintains control over every aspect of its production process, from gold mining and gemstone extraction to jewelry manufacturing and global distribution.

As a prominent player in the industry, GEMXX stands out as a leading producer of high-quality finished Ammolite jewelry. Notably, it holds the distinction of being the sole public company engaged in Ammolite mining worldwide. In addition to its Ammolite operations, the company is actively involved in gold mining and prides itself on its ability to design and manufacture exquisite jewelry pieces and exceptionally rare, natural fossil decor items for clientele around the globe.

One of GEMXX’s key advantages lies in mining its own gold reserves to be utilized in its jewelry production. This strategic approach provides the company with a cost-saving edge over other producers in the market.

Ammolite is similar to black opal and is a biogenic gem like amber and pearl. It is derived from the fossilized shells of ammonites, a group of extinct marine nautiluses.

GEMXX’s world class gemstone cutters and jewelry designers are continuously leading the Ammolite industry. Its team believes in the company’s philosophy, vision and goals, and works every day to continue to drive the Ammolite industry to the forefront of the gem world.

The company has offices in Las Vegas and Hong Kong.

Projects and Operations

GEMXX has formulated an ambitious growth plan that, while challenging, is deemed attainable. The company’s strategy revolves around bolstering its market share through several key initiatives. Firstly, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.

Secondly, the company plans to venture into untapped markets strategically. By identifying and targeting new areas, GEMXX seeks to establish a presence in regions that present promising opportunities for growth.

Additionally, GEMXX envisions growth through acquisitions. By considering and integrating key services, distribution networks and retail outlets into its fold, the company aims to consolidate its market position and capitalize on synergies for enhanced success.

To cater to the rising demand for its products, GEMXX has placed a primary focus on increasing gemstone production. The company’s southern properties, situated in Alberta, Canada, hold valuable deposits of rough Ammolite gemstone. By tapping into these resources, GEMXX is poised to meet the demand for its exquisite gemstone products and further fuel its expansion plans.

 

GEMXX possesses significant mineral assets in the form of a Mineral Work Permit covering an 800-acre area and two Ammonite Shell Mineral agreements encompassing 217 acres within the same region. The company’s management effectively operated mines in close proximity to these properties. Moreover, core sampling, along with fossil outcroppings on the riverbanks, confirms a substantial Ammolite resource present in these designated areas.

Both the Mineral Work Permit and the Ammonite Shell Mineral agreements grant GEMXX unrestricted access to all Ammolite resources within their respective demarcations. Notably, the company is not obligated to pay any royalties to third parties, thereby enabling GEMXX to fully capitalize on the potential of these valuable resources.

Furthermore, there are no stringent regulatory conditions that GEMXX must fulfill to gain or retain access to the Ammolite deposits. This freedom of access allows the company to proceed with its mining and production operations unimpeded, providing an advantageous position for future growth and success.

In March 2023, GEMXX made a significant announcement, revealing its acquisition of a 50% ownership stake in Crazy Horse Mining Inc., a Canadian gold mining company with assets situated in the province of British Columbia. As part of this deal, Crazy Horse’s assets, which encompass a 100% interest in two gold projects, called Snow Creek and Rosella Creek, spread across a substantial area exceeding 700 acres, now become part of GEMXX’s portfolio.

Under the terms of this strategic partnership, GEMXX and Crazy Horse will jointly share the expenses related to mining operations on these projects. Additionally, the two companies will share the gold produced from these ventures, leading to a collaborative and mutually beneficial arrangement.

Initial tests conducted on the property, combined with gold already recovered this season, confirm all expectations for the claims and substantiate the company’s estimated extraction target of over 100,000 ounces of easily recoverable gold. To validate and provide a more comprehensive assessment of this estimate, an S-K 1300-compliant Resource Report is scheduled to be conducted during the summer of 2023.

By acquiring this stake in Crazy Horse Mining Inc., GEMXX has positioned itself for further growth in the gold mining sector and is poised to capitalize on cost of goods savings in its jewelry business.

Market Opportunity

Leading independent market research companies such as Data Monitor and GIA estimate the worldwide market for luxury or premium lifestyle products, which include gems and jewelry, at over $90 billion annually and growing. Ammolite sales around the world have seen unprecedented growth over the past 20 years. Worldwide retail sales are now estimated to be over $100 million.

Ammolite jewelry and fossils are featured aboard cruise ships and can be found in specialty shops in almost every cruise port in North America. Asian markets have grown since feng shui master Edward Li called Ammolite the most influential stone of the new millennium, referring to it as the “Seven Color Prosperity Stone.” Home shopping channels in Japan, Australia, France, Germany, the UK, Canada and the U.S. have all featured Ammolite jewelry.

Ammolite and ammonites can also be found on many ecommerce sales platforms, including Amazon, eBay and Etsy. Ammolite is sold around the world in tourist and traditional jewelry markets. The company has established customers in home shopping channels, cruise tourism, jewelry retailers, Asian feng shui markets, Asian retail markets and ecommerce platforms.

Management Team

With over 160 years in Ammolite management, operations, and sales, GEMXX possesses an unparalleled wealth of knowledge and expertise. Its team members have extensive backgrounds in every facet of the Ammolite business, allowing the company to excel in product development, maintain rigorous quality control measures, and maximize profitability. The breadth and depth of the GEMXX team’s experience enable the company to navigate the industry with precision, ensuring that GEMXX remains at the forefront of the Ammolite market. GEMXX leverages its collective wisdom to drive innovation, deliver exceptional products, and optimize business strategies to achieve long-term success.

Jay Maull is Founder, CEO and Chairman of GEMXX. With a career spanning more than three decades, he has been deeply involved in the Ammolite industry, from mining and production to marketing. He has owned and operated the world’s largest Ammolite mine and has delivered exceptional Ammolite products to customers across all continents. He has also established the world’s largest Ammolite ecommerce platform.

Richard Clowater is President of GEMXX. He is a skilled sales and marketing professional with a focus on research, data analysis and strategic planning. He has successfully implemented initiatives to expand markets, boost profits and foster customer loyalty. He has an impressive track record of negotiating sales and contracts worth over $250 million with influential stakeholders, including key purchasing personnel, C-suite executives and government entities at all levels.

Tom Dryden is a Vice President of GEMXX and brings a wealth of experience and expertise to the production and marketing of Ammolite, spanning over 30 years. His extensive involvement in the industry has granted him unparalleled knowledge of the Bearpaw Ammonite bearing formations. As a recognized authority in the field, Mr. Dryden’s research and papers on Canadian Ammonites have garnered global recognition, being published worldwide. In his role at GEMXX, Mr. Dryden assumes the responsibility of overseeing the company’s Canadian-based production facilities. 

P. K. Chung is Business Manager Asia at GEMXX. With a track record of over 25 years in Ammolite business management, production and marketing in Asia, she is a recognized authority in the industry. Based in the Hong Kong gem district, she possesses an intricate understanding of the Asian gem and jewelry markets, including market dynamics, consumer preferences and industry trends specific to the region. Her strategic insights and deep connections enable GEMXX to thrive in this influential market.

GEMXX Corp. (OTC: GEMZ), closed Monday's trading session at $0.023, off by 16.5154%, on 1,000 volume. The average volume for the last 3 months is 20,705 and the stock's 52-week low/high is $0.0172/$0.19.

Recent News

Advanced Gold Exploration Inc. (CSE: AUEX) (FSE: 4TG) (OTC: AUHIF)

The QualityStocks Daily Newsletter would like to spotlightFathom Advanced Gold Exploration Inc. (CSE: AUHIF) (FSE: 4TG) (OTCQB: AUHIF) .

Advanced Gold Exploration Inc. (CSE: AUEX) (OTC: AUHIF) (FSE: 4TG), formerly Advance United Holdings Inc., is a junior mining company bringing an entirely different approach to the mining industry. Advanced Gold Exploration doesn’t intend to become a mining company. Rather, it has acquired a portfolio of undervalued gold properties and is increasing their value through the application of modern technology. The object is to eventually monetize the projects to add value for its shareholders.

Advanced Gold Exploration has a growing pipeline of similar properties that it is looking to acquire. The company is involved exclusively in the acquisition and advancement of past gold projects – with no intent to bring them back into production. It leaves the actual gold mining to others who are experts in that area.

Advanced Gold Exploration’s expertise is in identifying and acquiring undervalued properties with significant historical work which were previously not economically viable, but that the company believes have economic value at today’s gold prices. Advanced Gold Exploration funds the reworking of historic data and applying modern technology to underwrite new qualified reports that document quantifiable resources and reserves to current standards, thereby recognizing the current value of the projects.

The company’s purpose is to bring immediate and long-term value to its partners and shareholders while seeking to eliminate exploration risk. Advanced Gold Exploration believes that the future of gold is strong, and it will be part of that future.

The company is headquartered in Toronto.

Projects

The Melba Property is the site of a former producing gold mine located about 15 kilometers north of the gold mining center of Kirkland Lake, Ontario. The project is located in the Abitibi Greenstone Belt, part of the largest gold producing area of Canada. Visible gold can be identified in quartz veins on the surface and high-grade gold intersections have been obtained in drilling by AUEX. No exploration has been carried out on the extensions of the veins to the north or south of the surface exposures in swamp covered areas.

The Doyle Property lies in the Batchawana Greenstone Belt located north of Sault Ste. Marie, Ontario. Past drilling identified high-grade gold deposits in three areas of the property. Follow up studies are needed on all three sites. Exploration has not been carried out to follow-up the high-grade gold intersections. Further work will focus on expanding the areas of known gold mineralization.

The Landrum Property in Edgefield County, South Carolina, is in the Carolina Gold Belt, home of at least five past producing gold mines and one currently producing gold mine. The area was the site of the first gold rush in the U.S. in the early 1800s, predating 1849 California. The area has recently become of interest due to gold bearing intersection on a nearby property where 62.5 meters graded 8.5 G/t gold in a recent drillhole. Gold can still be panned in some streams in the area. Identified veins consist of silicified zones generally made up of 20-50% and vary in thickness from less than a meter to 10 meters.

The Paint Lake Road Property is located in Wawa, Ontario, and is less than five kilometers from Wesdome’s operating Mishi Open Pit gold mine. Gold deposits have been found to the north, east and south of the property. A recent geophysical survey on the neighboring property has pointed to a prospective mineralized horizon which appears to trend onto the property.

Market Opportunity

The World Gold Council, the industry association for the world’s gold producers, estimated in 2023 the physical financial gold market, which is made up of bars, coins, gold ETFs and central bank reserves, is worth nearly $5 trillion. The council reports that gold mine production adds approximately 3,500 tons of the precious metal to the world’s supply annually, equivalent to about 2% growth.

Recently the gold price has reached new highs on multiple days and is tracing a trend upward.

This historical scarcity and relatively slow production of new supply, as compared to other commodities, is a primary reason gold has retained its value for millennia, according to the council.

Management Team

James Atkinson, M.Sc., P. Geo., is CEO of Advanced Gold Exploration. An experienced exploration geologist and project manager with over 50 years of experience, he has spent his career in mineral exploration and mining. He has designed and managed multimillion dollar programs searching for and discovering various commodities, including industrial minerals. These projects involved geophysical, geochemical and drilling programs, as well as prospecting and geological mapping. He has also negotiated options and purchase deals for mineral properties and raised financing for exploration. He recently completed a transaction which resulted in cash and shares to the company. The result was a special distribution of publicly trading shares to the existing shareholders.

Andrew Ramcharan, Ph.D., P. Eng., is President of Advanced Gold Exploration. He has 20 years’ unique experience in the mining industry, which includes investor relations, project evaluation, operations, capital markets, consultancy and investment banking. He has a track record of growing companies significantly, with recent success at Roscan Gold with over $100 million of value creation in less than 14 months. He has created and implemented investor relations policies and corporate strategies with significant success. He completed over 300 project evaluations globally on many commodities, proposed over 40 for different investment strategies and completed two majors take over (worth of $800 million and $1.5 billion in capital cost). He directly assisted in putting four mines in production and significant growth of numerous companies, including IAMGOLD. At Sprott, he was conducting project evaluation and successfully deployed over $500 million – the most deals in any year.

Radovan Danilovsky, CIM, is CFO of Advanced Gold Exploration. He is an experienced small-cap executive in the junior mining sector. He is also an experienced investment manager and currently is a registered Portfolio Manager with Wealthera Inc. He has served as a Managing Director, Portfolio Manager and Chief Compliance Officer of Orthogonal Capital Management Corp. Prior to that, he was an investment analyst at Accilent Capital Management Inc. He is a graduate of the University of Toronto and earned master’s degrees from UPMC Sorbonne University and ESSEC Business School in Paris.

Advanced Gold Exploration Inc. (OTC: AUHIF), closed Monday's trading session at $0.02, even for the day. The average volume for the last 3 months is and the stock's 52-week low/high is $0.0189/$0.095.

Recent News

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers

QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal

The QualityStocks Sponsored News

The QualityStocks DailyNetwork Sponsors

CannabisNewsWireCanadianCannabisNewsWireCNW420CannabisNewsWatchCBDWireCryptoCurrencyWireGot Stocks?Got Stock Tips?Green On The StreetHempWireNewsInvestorOutreachCenterMissionIRMissionIR MediaMissionPR MissionSMRNetworkNewsWireNetworkNewsWatchNetworkWireQualityStocks MediaQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsSmallCapSocietyTiny GemsTip.usTraderPower
ActionStockPicksAgressive StocksBetting On Wall StreetGreen Car StocksGreen Energy StocksHomeRunStocksInvestorBrandWireQStocksStock BeatsStockTipsStocks To Buy NowTerrificStocks

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.

370 N. Hayden Rd.
Suite 123-591
Scottsdale, AZ 85251
480-374-1336

Please read Disclaimers for FULL Compensation Disclosures and other disclaimers.

Copyright © .